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Abstract 
New advances in the life sciences and engineering have enabled researchers to 
construct increasingly accurate experimental models of in vivo conditions. A logical next 
step would be to connect these discrete modules into increasingly complex networks 
forming an integrated, microphysiological model of the human body (a human on a chip 
or HOC). Such a system would be a powerful tool for probing myriad aspects of human 
health and disease. However, a generalizable HOC platform would require a rational, 
top-down design strategy and to date precious little time or energy have been spent 
examining such a problem. Here, we attempt to construct such an approach in three 
stages. First, we develop a cell-dense, 3-dimensional model of adipose tissue and 
demonstrate a functional response as measured by insulin-induced glucose uptake. We 
then use this microtissue construct to conduct a series of experiments that identify 
crucial parameters and potential problems for an HOC design strategy including control 
of cellular metabolism, circulating media or “blood” volume, and relative organ sizes. 
Finally, we address those issues using a variety of workarounds, compromises, and 
design criteria to induce in vivo-like system behavior, even in the face of apparently 
strange component values. We close by proposing design strategies for a 
physiologically relevant, 5-organ HOC that incorporates these lessons. 
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Chapter 1:  
Introduction and Thesis Overview 
 
1.1 The rising cost of biomedical research 
As human health standards in the developed world have risen, so too have the 
costs of improving human health. This trend is starkly illustrated in the exponentially 
increasing cost of drug development (1, 2), but can also be seen in declining returns on 
biomedical research funding and the rising cost of domestic healthcare (3–5). In part, 
this growth is a natural consequence of progress: easy-to-discover drugs get discovered 
and regulatory standards tighten with an expanding knowledge base and drug library 
(2). As a result, scientists are faced with increasingly difficult problems and an 
increasingly constrained parameter space in which to solve them. 
These trends, while challenging in their own right, are further exacerbated by a 
gap in knowledge that emerges between well-controlled, cost-effective experimental 
platforms (e.g. in vitro cell culture) and more complex, expensive approaches (e.g. 
clinical or animal studies). Conventional laboratory cell culture typically fails to capture 
the nuanced microenvironment of the body (6, 7). Animal studies, while offering the 
complexity of a genuine, living system, present their own challenges in throughput, 
translatability, and accuracy (8–11). Moreover, that complexity may frustrate 
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mechanistic studies necessary to explore specific hypotheses regarding drug action, 
disease progression, or toxin effect.  
A well-controlled, cost-effective, and physiologically relevant experimental platform 
would address these concerns. Furthermore, such a system would allow a fundamental 
reworking of the paradigm under which biomedical knowledge is produced. New 
medical entity (NME) development, for example, can see as much as 90 percent 
attrition at the clinical stages – the most expensive steps of the process (12). Indeed, a 
sensitivity analysis of drug development identified Phase II and Phase III attrition as the 
top two drives of NME cost (13). Therefore, shifting NME attrition to pre-clinical stages 
by using improved in vitro models could eliminate “false positives” (i.e. drug candidates 
that appear promising but fail in clinical trials) and result in substantial gains for 
development efficiency. Those gains could be “reinvested” to keep other NME’s in the 
pipeline for longer or more detailed periods of study, thereby reducing the number of 
“false negatives” as well. Surprisingly, that same analysis found that lead optimization 
was the third leading cost driver, indicating that the improved in vitro models could be 
drivers of substantial cost savings in and of themselves (13). 
1.2 Microengineered models of biology 
One way to address these issues is to build models that better represent the 
systems under study. Microfluidics and other microengineering techniques offer 
scientists many ways to control chemical, mechanical, and dimensional cues in the 
cellular microenvironment efficiently and with great precision (14, 15). In the late 1990’s, 
a series of advances such a cleanroom batch processing and silicone micromoldling 
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rendered these advanced engineering techniques available to biomedical research labs 
across the word (16). By shrinking the scale of experiments, scientists reaped benefits 
associated with smaller material requirements, the potential for integrated sensing, 
actuation, and high-throughput processing. They were also able to take advantage of 
the unique properties of the microscale: fast mass and energy transport, large surface 
area to volume ratios, and laminar flow (17–19).  
1.2.1 Organ on a chip 
Coupled with more exquisite microfabrication techniques, microfluidics affords 
researchers the opportunity to construct complex, integrated systems capable of 
recapitulating key aspects of organ structure and function in a miniaturized platform – 
an “organ on a chip” or OOC (6, 7). Typically, these systems include chemical, 
mechanical and dimensional aspects that mimic the in vivo microenvironment and 
exhibit a greater range of function than conventional cell culture would allow. For 
example, lung function may be studied conventionally by plating lung epithelial cells in 
monolayer culture on a petri dish. Instead, a lung on a chip device allows for 
compartmentalized culture of both endothelial and epithelial cells on opposite sides of a 
permeable membrane. Furthermore, vacuum actuation provides cyclic, in vivo-like strain 
and fluid flow can be tuned to impart realistic shear stresses and introduce various 
cytokines, bacterial infections, or immune cells (20). Systems such as this provide a 
much richer degree of information and control compared to conventional in vitro 
experiments and scientists have developed on-chip models to study a variety of organ 
systems including the alveolus, heart, gut, kidney, and blood brain barrier (21–25). 
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1.2.2 Human on a chip 
A natural extension of the concepts behind OOCs is the goal of developing a 
microphysiological model of the body or a “human on a chip” (HOC). In some ways, the 
problems confronting researchers in this field are akin to those faced by cartographers: 
just as mapmakers must determine the proper scale and amount of detail to include in a 
chart, so too must scientists and engineers determine the appropriate level of features 
for an HOC (26, 27). Too few details will result in a testing system that fails to provide 
relevant information or insights. Too many details yield a device that is unwieldy and 
indecipherable. Along with technical issues of how to best control the microenvironment 
and direct cell behavior, researchers must also struggle with establishing how to design 
these miniaturized systems.  
Perhaps all present efforts to recapitulate interaction among organs within a 
microfluidic system can trace their ancestry to milk bottles. Although this pioneering 
arrangement was decidedly macro-fluidic, Michael Shuler and his colleagues at Cornell 
University broke important new ground when they published their first “cell culture 
analog” in 1995 by connecting compartmentalized “organs” contained in the 
aforementioned milk bottles. With motivations to improve on both in vitro and in vivo 
experiments that still echo today, the authors devised a microfluidic system to 
investigate naphthalene toxicity among three distinct organs (lung, liver, and “other 
tissue”) connected by tubing filled with cell culture media and driven by pumps to mimic 
the blood (28). Building on the milk bottle systems nearly a decade later, Viravaidya et 
al. successfully demonstrated interaction between lung, liver, fat, and “other tissue” 
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compartments in what was likely the first microfluidic HOC. This study again 
investigated naphthalene toxicity and observed that metabolites generated in the liver 
reduced glutathione production in the lungs and resulted in cell death (29). At the 
system level, Shuler and company design their HOC by reducing organ size linearly 
with system mass while compartment volumes and flow rates are selected to maintain 
residence times between humans and the HOC (30). 
Later studies investigated the action of Tegafur, an anticancer prodrug, within an 
HOC comprising lung, liver, and bone marrow domains and realized on-chip 3D-
hydrogel culture to support enhanced liver cell function and evaluated the results in light 
of a physiologically-based pharmacokinetic and pharmacodynamics (PB-PKPD) model 
(31, 32). When sufficient information such as drug behavior and metabolic rate 
constants are available, this combination of experimental and modeling approaches 
represents a powerful tool for designing and interpreting HOC-based experiments. 
Another effort investigated the effects of polystyrene nanoparticles on a two-circuit 
HOC: one course represented the gastrointestinal (GI) tract and was used to dose the 
nanoparticles by means of (simulated) oral exposure and a second mimicked the 
systemic circulation of the body. The two loops communicated via a two-layer co-culture 
intestinal compartment with the apical side (representing the lumen of the small 
intestine) being exposed to the GI/nanoparticle solution (33). 
Rather than rely on linear scaling and residence time calculations to inform HOC 
design, John Wikswo of Vanderbilt University has proposed and HOC containing organ 
compartments designed according to empirical relationships between organ size and 
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animal mass (26, 34). While robust within the original dataset, extrapolating these 
relationships to HOC’s of small total system mass remains a challenge. Arti Ahluwalia 
and her colleagues at the University of Pisa use quarter power scaling rules (QPSRs, 
see §1.3 for more information) to guide HOC design (35, 36). Coupled with these 
relationships, shear stress, principles of Euclidean geometry, and mass transport 
calculations govern the group’s approach (37, 38). Microfluidic studies examined the 
effect of HOC culture on interactions between liver and endothelial cells. Although this 
study only contained two “organs,” the ability to apply shear stress was a key 
consideration. Differences were not only observed between the dynamic, microfluidic 
system and monoculture, but also between the HOC system and traditional static co-
culture (39, 40). More recently, Ahluwalia et al. have begun to advocate scaling by cell 
number, as it produces more consistent results in vitro and avoids challenging design 
requirements that may arise when metabolism and surface area are scaled by different 
exponents (41). 
Other groups simply design their HOC according to organ mass. Yu and 
colleagues similarly attempted a proof of concept device examining the interaction of 
four organs (fat, kidney, liver, and lung). Each organ was represented by a cell-laden 
hydrogel and patterning of the system was controlled by microfabricated post arrays. 
Furthermore, the group incorporated Transforming Growth Factor Beta eluting gelatin 
microspheres and showed that varying levels of the cytokine can affect organ-specific 
behavior of each compartment (42). For their HOC device, Marx et al. scaled their organ 
compartments by mass. The two organ skin-liver system was capable of supporting a 
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variety of culture methods in each compartment. Despite the inclusion of only two 
organs, this device is an excellent example of microfluidic integration as the authors 
included an on-chip peristaltic pump to drive the recirculating fluid flow and reduce the 
device’s footprint. Perhaps most notable about this work however is the inclusion of 
actual patient biopsies in the lung compartment of the HOC (43). While preliminary, 
these results highlight the potential of HOCs for applications in personalized medicine. 
A later report claimed the ability to examine absorption, distribution, metabolism, and 
excretion (ADME), key pharmacokinetic parameters (44). 
Imura, Yoshimura, and Sato developed HOC for testing the anticancer drugs 
Tegafur and Cyclophosphamide that – in addition to an integrated two-circuit system – 
included stomach, liver, and tumor compartments. Cells in the stomach region were 
cultured on a porous membrane and served as the barrier between an acidic 
gastrointestinal circuit that was used to introduce the drugs to device and a blood circuit 
used to circulate the drugs and their metabolites among the organs. Importantly, this 
system allowed the researchers to carry out their experiments using only one-fifth the 
cells and one-tenth the reagents that would have been required by conventional cell 
culture techniques (45). These efforts are summarized in Table 1-1. 
1.3 Relating animal size to biology 
The complexities associated with changing animal mass have long been known 
and offer HOC designers some guidance when selecting various parameters for their 
systems. Galileo posited that size – be it biological or structural – possessed an upper 
limit (46). More recently, scientists have used scaling arguments to assess whether the 
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dinosaur Tyrannosaurus Rex was a capable runner (47). Although their findings 
indicated not, T. Rex was still theorized to be more capable of sprinting than a 6,000 kg 
chicken. In 1926, J.B.S. Haldane published an essay “On Being the Right Size” which 
provided a spirited and occasionally colorful argument that each animal carried a most 
convenient size and that for every change in size a change in form follows (48). 
Importantly, Haldane extended his treatment beyond mechanical scaling (e.g. bone 
cross section versus body mass or the implications of “getting wet” for animals of 
different sizes) and touched on issues of scaling in nutrition, sense, and metabolism. 
“On Being the Right Size,” however, still relied on geometric arguments to explore 
how different aspects of an organism change with mass, M. For example, Haldane 
assumed heat generation for warm-blooded mammals depended on mass and surface 
area – i.e. that it grew in proportion to M2/3. A little over a decade later, Kleiber boldly 
suggested that energy expenditures grew commensurate with M3/4 instead (36). At first 
met with skepticism, Klieber’s quarter power scaling rule has gradually grown to be 
widely accepted (49). Remarkably, a host of other vital parameters follow a similar 
quarter-power pattern (50, 51). 
The source of the three-quarter power exponent instead of the expected two-thirds 
– the source of that extra 1/12 – had long been debated until West, Brown, and 
Einquist, in 1997, demonstrated that it arose as a consequence of the evolutionarily 
optimized nutrient distribution system of animals (35, 52). Later Banavar et al. adjusted 
and confirmed the theory (53). In addition to validating Klieber’s work over a half century 
after its publication, these studies demonstrated a clear mechanism of how not just 
  9 
metabolism, but nearly every other vital parameter (lifespan, cardiac output, urination, 
etc.) depended on mass in a predictable way, generally mass raised to a quarter power 
or multiple thereof (50, 51, 54). Using this array of quarter power scaling rules, scientists 
can predict how animal life would look at many different sizes. QPSRs, then, provide 
designers of miniaturized physiologic models with powerful guidance for building 
relevant, scalable systems. However, there are no animals smaller than 1g that could 
confirm these predictions (52, 55). Beyond that, technical limitations (e.g. difficulties 
associated with small blood volumes) may force designers to deviate from the 
predictions of QPSRs (26, 44, 56). Whether and to what extent these changes may 
affect model fidelity remains an open question. 
 
1.4 Dissertation overview 
Table 1-1 provides a concise summary of notable HOC’s to date and represents 
many outstanding efforts at engineering an integrated, physiologically relevant 
biomedical research platform. Nevertheless, most work in the field moves forward 
lacking a coherent, generalizable set of rules to guide design. Researchers may 
develop HOC’s that work for a single stated purpose (e.g. observing the action of a 
specific anti-cancer drug), but have little hope of supporting any further exploration. 
Such cases, then, are of little use when applied to discovery. Unfortunately, that is 
exactly where the true power of an integrated, microphysiologic model of human health 
lies: the drug with an unsuspected metabolite, the disease with an unknown systemic 
effect, the adverse reaction with an unanticipated synergy (Figure 1-1) (56). Therefore, 
we endeavor to develop a set of design criteria for a generalized HOC capable of 
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providing relevant experimental results for a variety of inputs – regardless of a priori 
knowledge. If successful, this effort will help to bridge the gap between in vitro research 
and in vivo application (Figure 1-2, A). 
To accomplish this, we work from the bottom up (Figure 1-2, B). In Chapter 2, we 
develop and characterize a cell-dense, 3-dimensional model of fat tissue using hanging 
drop culture. We then apply these adipospheroids to develop an explicit, experimentally 
supported set of HOC design rules in Chapter 3. Following those guidelines, Chapter 4 
formulates a comprehensive, integrated strategy for a 5-organ, physiologically relevant 
and metabolically accurate model of human health. As necessary, we apply engineering 
controls to induce human-like cell behavior. Where design rules set challenging 
parameters, we examine potential workarounds and the implications thereof. 
Synthesizing conclusions from these experiments and from theoretical analyses, we 
conclude with a brief analysis of our HOC’s suitability and leave the reader with a 
comprehensive set of design criteria for an integrated microfluidic model of the human 
body.  
  11 
1.5 Works cited 
1.  Munos B (2009) Lessons from 60 years of pharmaceutical innovation. Nat Rev 
Drug Discov 8(12):959–968. 
2.  Scannell JW, Blanckley A, Boldon H, Warrington B (2012) Diagnosing the decline 
in pharmaceutical R&D efficiency. Nat Rev Drug Discov 11(3):191–200. 
3.  Bowen A, Casadevall A (2015) Increasing disparities between resource inputs 
and outcomes, as measured by certain health deliverables, in biomedical 
research. Proc Natl Acad Sci 112(36):11335–11340. 
4.  Catherine Rampell (2012) Why Tuition Has Skyrocketed at State Schools. N Y 
Times. Available at: http://economix.blogs.nytimes.com/2012/03/02/why-tuition-
has-skyrocketed-at-state-schools/?_r=0 [Accessed February 1, 2015]. 
5.  Healthcare CPI: All Urban Consumers (2015) Available at: 
http://www.bls.gov/data/ [Accessed March 7, 2015]. 
6.  Moraes C, Mehta G, Lesher-Perez SC, Takayama S (2012) Organs-on-a-Chip: A 
Focus on Compartmentalized Microdevices. Ann Biomed Eng 40(6):1211–1227. 
7.  Bhatia SN, Ingber DE (2014) Microfluidic organs-on-chips. Nat Biotechnol 
32(8):760–772. 
8.  Bracken MB (2009) Why animal studies are often poor predictors of human 
reactions to exposure. JRSM 102(3):120–122. 
9.  Sundstrom LE (2007) Thinking inside the box. EMBO Rep 8(1S):S40–S43. 
10.  Seok J, et al. (2013) Genomic responses in mouse models poorly mimic human 
inflammatory diseases. Proc Natl Acad Sci 110(9):3507–3512. 
11.  Greek R, Menache A (2013) Systematic Reviews of Animal Models: Methodology 
versus Epistemology. Int J Med Sci 10(3):206–221. 
12.  Kola I (2008) The State of Innovation in Drug Development. Clin Pharmacol 38 
Ther 83(2):227–230. 
13.  Paul SM, et al. (2010) How to improve R&amp;D productivity: the pharmaceutical 
industry’s grand challenge. Nat Rev Drug Discov. doi:10.1038/nrd3078. 
14.  Christopher S. Chen, Milan Mrksich, Sui Huang, George M. Whitesides, Donald 
E. Ingber (1997) Geometric Control of Cell Life and Death. Science 276:1425–
1428. 
  12 
15.  Takayama S, et al. (2003) Selective chemical treatment of cellular microdomains 
using multiple laminar streams. Chem Biol 10(2):123–130. 
16.  McDonald JC, et al. (2000) Fabrication of microfluidic systems in poly 
(dimethylsiloxane). Electrophoresis 21(1):27–40. 
17.  Beebe DJ, Mensing GA, Walker GM (2002) Physics and Applications of 
Microfluidics in Biology. Annu Rev Biomed Eng 4(1):261–286. 
18.  Walker GM, Zeringue HC, Beebe DJ (2004) Microenvironment design 
considerations for cellular scale studies. Lab Chip 4(2):91. 
19.  Paguirigan AL, Beebe DJ (2009) From the cellular perspective: exploring 
differences in the cellular baseline in macroscale and microfluidic cultures. Integr 
Biol 1(2):182. 
20.  Huh D, et al. (2010) Reconstituting Organ-Level Lung Functions on a Chip. 
Science 328(5986):1662–1668. 
21.  Douville NJ, et al. (2011) Combination of fluid and solid mechanical stresses 
contribute to cell death and detachment in a microfluidic alveolar model. Lab 
Chip 11(4):609–619. 
22.  Grosberg A, Alford PW, McCain ML, Parker KK (2011) Ensembles of engineered 
cardiac tissues for physiological and pharmacological study: Heart on a chip. Lab 
Chip 11(24):4165. 
23.  Kim HJ, Huh D, Hamilton G, Ingber DE (2012) Human gut-on-a-chip inhabited by 
microbial flora that experiences intestinal peristalsis-like motions and flow. Lab 
Chip 12(12):2165. 
24.  Jang K-J, Suh K-Y (2010) A multi-layer microfluidic device for efficient culture 
and analysis of renal tubular cells. Lab Chip 10(1):36–42. 
25.  Booth R, Kim H (2012) Characterization of a microfluidic in vitro model of the 
blood-brain barrier (μBBB). Lab Chip 12(10):1784. 
26.  Wikswo JP, et al. (2013) Engineering Challenges for Instrumenting and 
Controlling Integrated Organ-on-Chip Systems. IEEE Trans Biomed Eng 
60(3):682–690. 
27.  Stokes C, Cirit M, Lauffenburger D (2015) Physiome-on-a-Chip: The Challenge 
of “Scaling” in Design, Operation, and Translation of Microphysiological Systems: 
Physiome-on-a-Chip. CPT Pharmacomet Syst Pharmacol 4(10):559–562. 
  13 
28.  L. M. Sweeney, M. L. Shuler, J. G. Babish, A. Ghanem (1995) A Cell Culture 
Analogue of Rodent PHysiology: Application to Naphthalene Toxicology. Toxicol 
Vitro 9(3):307–316. 
29.  Viravaidya K, Sin A, Shuler ML (2004) Development of a Microscale Cell Culture 
Analog To Probe Naphthalene Toxicity. Biotechnol Prog 20(1):316–323. 
30.  Abaci H, Shuler M (2015) Human on a chip Design Strategies and Principles for 
Physiologically Based Pharmocokinetics/Pharmacodynamics Modeling. Integr 
Biol. doi:10.1039/C4IB00292J. 
31.  Sung JH, Shuler ML (2009) A micro cell culture analog (µCCA) with 3-D hydrogel 
culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anti-
cancer drugs. Lab Chip 9(10):1385. 
32.  Sung JH, Kam C, Shuler ML (2010) A microfluidic device for a pharmacokinetic–
pharmacodynamic (PK–PD) model on a chip. Lab Chip 10(4):446. 
33.  Esch MB, Mahler GJ, Stokol T, Shuler ML (2014) Body-on-a-chip simulation with 
gastrointestinal tract and liver tissues suggests that ingested nanoparticles have 
the potential to cause liver injury. Lab Chip 14(16):3081. 
34.  Wikswo JP, et al. (2013) Scaling and systems biology for integrating multiple 
organs-on-a-chip. Lab Chip 13(18):3496. 
35.  West GB, Brown JH, Enquist BJ (1997) A General Model for the Origin of 
Allometric Scaling Laws in Biology. Science 276(5309):122–126. 
36.  Kleiber M (1947) Body size and metabolic rate. Physiol Rev 27(4):511–541. 
37.  Mattei G, Giusti S, Ahluwalia A (2014) Design Criteria for Generating 
Physiologically Relevant In Vitro Models in Bioreactors. Processes 2(3):548–569. 
38.  Sbrana T, Ahluwalia A (2012) Engineering Quasi-Vivo® in vitro organ models. 
New Technologies for Toxicity Testing (Springer), pp 138–153. 
39.  Guzzardi MA, Vozzi F, Ahluwalia AD (2009) Study of the crosstalk between 
hepatocytes and endothelial cells using a novel multicompartmental bioreactor: a 
comparison between connected cultures and cocultures. Tissue Eng Part A 
15(11):3635–3644. 
40.  Vozzi F, Heinrich J-M, Bader A, Ahluwalia AD (2008) Connected culture of 
murine hepatocytes and human umbilical vein endothelial cells in a 
multicompartmental bioreactor. Tissue Eng Part A 15(6):1291–1299. 
  14 
41.  Ucciferri N, Sbrana T, Ahluwalia A (2014) Allometric Scaling and Cell Ratios in 
Multi-Organ in vitro Models of Human Metabolism. Front Bioeng Biotechnol 2. 
doi:10.3389/fbioe.2014.00074. 
42.  Zhang C, Zhao Z, Abdul Rahim NA, van Noort D, Yu H (2009) Towards a human-
on-chip: Culturing multiple cell types on a chip with compartmentalized 
microenvironments. Lab Chip 9(22):3185. 
43.  Wagner I, et al. (2013) A dynamic multi-organ-chip for long-term cultivation and 
substance testing proven by 3D human liver and skin tissue co-culture. Lab Chip 
13(18):3538. 
44.  Maschmeyer I, et al. (2015) A four-organ-chip for interconnected long-term co-
culture of human intestine, liver, skin and kidney equivalents. Lab Chip 
15(12):2688–2699. 
45.  Imura Y, Yoshimura E, Sato K (2012) Micro total bioassay system for oral drugs: 
evaluation of gastrointestinal degradation, intestinal absorption, hepatic 
metabolism, and bioactivity. Anal Sci 28(3):197–7. 
46.  Galileo Galilei (1952) Dialogues concerning two new sciences (translated by H. 
Crew and A. De Salvio) (Dover, New York). 
47.  John R. Hutchinson, Paul Segall (2002) Tyrannosaurus was not a fast runner. 
Nature 415:1018–1021. 
48.  Haldane JB (1926) On being the right size. Harper’s Mag 152:424–427. 
49.  Stumpf MPH, Porter MA (2012) Critical Truths About Power Laws. Science 
335(6069):665–666. 
50.  Peters RH (1983) The Ecological Implications of Body Size (Cambridge 
University Press, New York). 
51.  Schmidt-Nielsen K (1984) Scaling: Why is Animal Size so Important? (Cambridge 
University Press, New York). 
52.  West GB, Woodruff WH, Brown JH (2002) Allometric scaling of metabolic rate 
from molecules and mitochondria to cells and mammals. Proc Natl Acad Sci U S 
A 99(Suppl 1):2473–2478. 
53.  Banavar JR, et al. (2010) A general basis for quarter-power scaling in animals. 
Proc Natl Acad Sci 107(36):15816–15820. 
54.  Yang PJ, Pham J, Choo J, Hu DL (2014) Duration of urination does not change 
with body size. Proc Natl Acad Sci 111(33):11932–11937. 
  15 
55.  Rittmeyer EN, Allison A, Gründler MC, Thompson DK, Austin CC (2012) 
Ecological Guild Evolution and the Discovery of the World’s Smallest Vertebrate. 
PLoS ONE 7(1):e29797. 
56.  Moraes C, et al. (2013) On being the right size: scaling effects in designing a 
human on a chip. Integr Biol 5(9):1149. 
 
  
  16 
 
 
 
Figure 1-1. Detection of unknown or unsuspected toxicities with an HOC 
Most current “HOC” efforts are merely multi-compartment organ systems designed to 
probe for specific and known toxicities or phenomena. A true, appropriately scaled HOC 
will be generalizable and therefore able to detect unknown or unsuspected effects.  
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Figure 1-2. Bridging the gap: a thesis overview 
(A) The gap between the way a drug or disease behaves in the body and cheap, fast, 
and easy in vitro experiments can be substantial and is a source of consternation for 
researchers in the biomedical sciences. Advances in microengineering represent an 
opportunity to engineer more realistic cell environments and interactions and thus 
generate actionable data about human health more quickly, accurately, and safely. (B) 
To bridge this gap, we develop a top-down design strategy for a microphysiological 
model of the human body (a “human on a chip” or HOC), ironically, from the bottom up. 
This thesis begins by developing and characterizing a cell-dense, 3-dimensional model 
of adipose tissue. Using that construct, we then conduct several experiments to 
formulate an explicit, experimentally-supported set of design rules. Finally, we apply 
those rules and examine the consequences of each and workarounds necessary to 
build a robust, physiologically relevant HOC platform.  
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Author Year Organs Design approach Application 
Shuler et 
al. (29) 2004 
Lung, liver, fat, 
“other tissue” 
Mass and residence time 
scaling 
Naphthalene 
toxicity 
Yu et al. 
(42) 2009 
Lung, liver, kidney, 
fat 
Hydrogel culture; cytokine 
eluting microspheres 
TGB-b efficacy, cell 
function 
Ahluwalia 
et al. (40) 2009 Liver, endothelium 
Alginate coating; WBE 
scaling; shear stress 
considerations 
Cell function 
Ahluwalia 
et al. (39) 2009 Liver, endothelium 
Alginate coating; WBE 
scaling; shear stress 
considerations 
Cell function 
Shuler et 
al. (31, 
32) 
2009, 
2010 
Liver, tumor, bone 
marrow, “other 
tissue” 
Mass and residence time 
scaling; hydrogel culture; 
PB-PKPD modeling 
Tegafur 
metabolism/toxicity 
Sato et al. 
(45) 2012 GI tract, liver, tumor 
Two circuit fluid flow; 
carrier bead culture 
Tegafur and 
cyclophosphamide 
metabolism/toxicity 
Marx et al. 
(43) 2013 Skin, liver 
Mass scaling; integrated 
pump; patient biopsies; 
transwell culture 
Cell function 
Shuler et 
al. (33) 2014 
GI tract, liver, “other 
tissue” 
Mass and residence time 
scaling; two circuit fluid 
flow 
Nanoparticle 
uptake 
Ahluwalia 
et al. (41) 2014 Liver, endothelium 
 Metabolic and surface 
scaling; cell number 
scaling 
Liver function, 
glucose uptake 
Marx et al. 
(44) 2015 
Intestine, liver, skin, 
kidney 
Patient biopsies, transwell 
culture, ADME, mass 
scaling 
mRNA expression, 
glucose and LDH 
levels 
 
Table 1-1. Summary of HOC efforts to date 
A comprehensive list of human on a chip efforts to date. Clearly, researchers use a 
variety of disparate, often ad hoc design approaches that yield systems only valid for a 
narrow, specific set of experiments. A design strategy for a generalized model system 
would help unlock the true promise of these microphysiological model systems. 
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Chapter 2:  
A Modular, 3-Dimensional Model of Fat Tissue 
Since adipose tissue in vivo is lobular, we seek to create a cell-dense, 3-dimensional 
model of fat tissue. Using a previously established hanging drop culture platform, we 
demonstrate control over cell number/spheroid size and examine differences in size and 
morphology as “adipospheriods” of different cell numbers mature. Further, enzyme 
linked immunosorbent assay data shows that these microtissue secrete leptin and 
adiponectin, two important adipokines. Although conventional, 2D fat cultures also 
expressed these biomarkers, they do so at a much higher leptin to adiponectin ratio, 
clinically correlated with increased insulin resistance. Indeed, insulin-induced glucose 
uptake assay showed as much, with small, 3D spheroids proving most efficient at 
glucose uptake. Therefore, we conclude that these adipospheroids represent functional 
fat. Moreover, these modular microtissues can be manipulated easily: size is controlled 
by altering the number of spheroids included in any given assay and structure can be 
controlled by gentle dispersion.  
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2.1 Introduction 
Adipose tissue is a critical regulator of homeostasis. Its canonical role is to 
respond to insulin signaling to remove glucose from the bloodstream. Not only can 
failure of this pathway be a sign of diabetes mellitus, but mounting evidence suggests 
implicates fat in the progession of other diseases as well (1). To be sure fat acts and an 
energy reservoir, storing triglycerides in times of plenty and mobilizing fatty acids during 
fasting. It is, however, also intimately involved in regulating its role in this process. 
Moreover, adipose-derived signaling molecules, or adipokines, play roles in many other 
important physiological pathways such as inflammation and vascular homeostastis. In a 
very real sense, fat acts as an endocrine organ unto itself (2). A common in vitro model 
of this critical organ is the 3T3-L1 murine cell line. Under appropriate conditions, these 
fibroblast-like progenitor cells undergo adipogenesis and, after about a week, emerge 
as mature fat (3, 4), capable of Glut4-mediated, insulin-induced glucose uptake (5–7). 
Since adipocytes and adipose tissue are generally lobular, we investigate whether 
spheroid culture in a cell-rich, 3D-culture platform would enhance any aspect of fat 
“function.” Previously, spheroid culture had been used to generate complex, ‘”Janus” 
tumor spheroids (8), had been found to induce in vivo-like morphology and function in 
liver cells (9), and had been used to grow fat spheroids as a model for inflammation (10, 
11). These efforts do examine key adipose biomarkers and signaling molecules, and 
indicate that 3D culture may indeed improve L1 phenotype. The authors of the previous 
studies stop short, however, of any functional assessment (such as glucose uptake) and 
relied on a poorly controlled process of self assembly. Therefore, we aim to develop a 
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3-dimensional in vitro fat model that offers precise control over cell number and 
spheroid size. In this chapter, we assess the quality of this micro tissue by examining 
morphologic changes, biomarker expression, and Glut4-mediated glucose uptake in the 
presence of insulin. 
2.2 Adipospheroid formation and differentiation 
2.2.1 Formation and differentiation 
Adipospheroids were grown in 384 well hanging drop (HD) plates developed 
previously to facilitate the formation of cell-laden microtissue for the study of cancer (12, 
13). Using through-holes and a surface tension “collar,” an array of 25 µL droplets can 
be maintained in place for weeks with minimal spreading or loss. Use of a liquid 
handling robot (CyBi Well; CyBio, Germany) for both cell seeding and media exchange 
greatly improves yield and throughput. 3T3-L1 murine preadipocyte cells (ATCC) were 
grown on tissue culture plastic in DMEM supplemented with 10 percent Newborn Calf 
Serum (NCS; Life Tech) and 1 percent antibiotic/antimycotic (anti/anti; LifeTech), 
passaged before 90 percent confluency, and used before passage 15. Adipospheroids 
were formed at Day -2 by seeding 40k cells/mL (1k cells/spheroid) or 320k cells/mL (8k 
cells/spheroid) in culture media supplemented with 0.24 percent Methylcellulose (A4M 
MethoCel, Dow Chemical), added to promote spheroid formation (14). Over two days, 
the cells self-assemble into 3D spheroids (Figure 2-1, A&B, top panels) and at Day 0, 
the media is changed to adipogenic induction media consisting of DMEM with 10 
percent fetal bovine serum (FBS; Gemini Biosciences), 1 percent anti/anti, 1 µg/mL 
insulin (Sigma), 10 µM Troglitazone (Sigma), 0.25 µM Dexamethasone (Sigma), and 10 
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nM Triiodothyronine (T3; Sigma). This particular media formulation was chosen 
because it induces very little glycerol secretion by the fat cells. Other methods that 
resulted in high glycerol concentrations made the media too viscous to handle and were 
therefore not pursued further. At Day 3, the media is changed to DMEM with 10 percent 
FBS, 1 percent anti/anti, and 1 µg/mL Insulin. At Day 5, the media is changed to DMEM 
with 10 percent FBS and 1 percent anti/anti. Experiments were performed on “mature” 
adipospheroids at Day 7. Conventional, 2D differentiation was performed on confluent 
cells grown on tissue culture following the same schedule outlined above. 
2.2.2 Adipospheroids increase in size and have altered morphology 
Over the course of differentiation, the adipospheroids become larger and more 
disperse (Figure 2-1, A&B, bottom panels). To quantify this change in morphology, we 
measure the area and circumference of the spheroid cross section using ImageJ to 
follow the contours of the tissue (Figure 2-1, C and D). For the 1k spheroid size, cross 
sectional area (CSA) increases by 6.5x and perimeter by 4.6x. The fold increases for 8k 
spheroids were 3.9 and 4.0 respectively. This increase in size demonstrates that cells 
are getting larger – typical during adipogenesis as the fibroblast-like preadipocytes 
mature and accumulate lipids (15–17). Since the change in circumference is greater 
than the square root of the change in CSA, the data also indicate that the cells are 
becoming less adherent – another hallmark of adipogenesis. Nooks and crannies that 
appear in the mature adipospheroids result in a larger perimeter for the same cell 
volume. Importantly, these changes in CSA and perimeter are not uniform across 
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spheroids, we hypothesis that smaller adiposhperoids experience a more efficient 
differentiation, possibly due to transport limitations and spatial constraints on cells at the 
core of the larger microtissue. 
To examine the structure of our adipospheroids more closely, we fixed, 
embedded, and sectioned both 1k and 8k spheroids at Day 0 (before induction media 
was added) and at Day 7 (when spheroid differentiation was considered complete). 
Staining the samples with hematoxylin and eosin, we present a cross-sectional view of 
the microtissue (Figure 2-2). Despite some deformation from the embedding and 
sectioning process, the stained slices generally match microscope images. The post-
differentiation slices show vacant, unstained regions within the cells which are the lipid 
vacuoles, the fat storage repositories of adipocytes. Comparing the presence and 
distribution of these vacuoles between the 1k and 8k spheroids, we observed an 
undifferentiated core at the center of the larger spheroid not present in the 1k condition, 
in agreement with our perimeter and area measurements of the microtissue. 
2.3 Adipospheroids secrete adipokine biomarkers 
We also examined the production of Leptin and Adiponectin (AdipoQ), two 
important adipokines involved in regulating homeostasis and metabolism. To further 
assess differentiation efficiency of our adipospheroids, we also assayed conventional, 
2D fat cultures prepared using the same differentiation protocol as the microtissue. At 
day 7, mature fat was washed thoroughly with PBS. Adipopheroids were loaded into u-
bottom, non-tissue culture treated well plates with 200 µL media and 2D fat was 
assayed in plate with 1 mL media. The conditions were placed in a cell culture incubator 
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for 24 hours at which point media samples were collected and frozen at -80 °C for later 
analysis with Quantikine ELISA kits (R&D Systems, Minnesota). 
ELISA results showed that Leptin production varied considerably among tissue 
sizes and architecture (Figure 2-3, A). Perhaps unsurprisingly, 8k spheroids, with their 
non-differentiated core, produced the least Leptin over the 24-hour incubation with only 
two of five samples showing Leptin content above the limit of detection for the assay. 
Conventional 2D culture produced significantly more (p<0.001) Leptin than either 3D 
condition. AdipoQ was produced by all samples with adipospheroids producing more 
than 2D culture and 1k spheroids producing more than their larger counterparts (Figure 
2-3, B). Clinically, Leptin to Adiponectin ratio (LAR) is a useful indicator of insulin 
resistance with higher LAR correlating with clinical measures of insulin resistance (18–
20). Plotting this ratio, the data indicates that the 3D adipose tissue may be more 
sensitive to insulin signaling (Figure 2-3, C). 
2.4 Functional assessment of adipospheroids 
2.4.1 Characterization of insulin-induced glucose uptake 
We sought to assess the functional characteristics of our adipospheroids by 
comparing the efficiency of insulin-induced glucose uptake between constructs of 
different size as well as conventional fat grown in 2D culture. To do this, mature fat was 
starved for 3 hours in Hank’s Buffered Salt Solution supplemented with Ca2+, Mg2+, and 
0.5 mM glucose (HBSS-g). Spheroids were collected manually using a cut-off 200 µL 
pipette tip to avoid shearing the cells since mature adipospheroids were quite delicate. 
Both adipospheroids and 2D fat were rinsed in HBSS-g. For the assay, adipospheroids 
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were placed in flat-bottom, glass vials and 2D was assayed in the 35 mm tissue culture 
dish it was grown in. At t=0-, all conditions were suspended in a known volume of 
HBBS-g buffer and sampled by removing 2 µL of media with a pipette. Subsequently 
(t=0+), HBSS-g with insulin was added to bring the total concentration of each 
experimental volume to 10 µg/mL insulin. A vehicle dose was added to bring the HCL 
concentration of each control (no insulin) condition to 0.05 mM HCl to account for acid 
in the insulin stock solution. Each volume was then placed in the incubator, gently 
agitated and sampled at t = 10, 30, 60, and 120 minutes.  
To analyze the change glucose present in the media (and thus glucose consumed 
by the cells), we used AccuChek Aviva glucose test strips (Roche) and a PGStat 128N 
PotentioGalvanoStat (AutoLab/Metrohm) as described by others (21). Briefly, we 
applied a 150 mV potential across the test strip, introduced the sample using a pipette, 
and monitored the resulting current for 60 seconds. Amperometric data was converted 
to glucose levels by taking the average of current values in a 10-second window 
occurring 5 seconds after the maximum current value was reached and calibrating 
against solutions of known glucose values. Data is reported as cumulative glucose 
uptake per cell and analyzed for statistical significance using ANOVA and Tukey’s post 
hoc test at confidence level α=0.05 (Figure 2-4). In general, 1k spheroids uptook 
glucose more efficiently on a per cell basis than 8k spheroids, which were slightly (and 
not significantly) more efficient than 2D culture. This trend persisted throughout the 
experiment, but inter-sample variability decreased as time wore on. 
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2.4.2 Discussion of size-based differences in glucose uptake efficiency 
The LAR data presented in §2.3 explains the variation between 3D and 2D fat – 
3D fat is more sensitive to insulin. However, that same data would also suggest that 8k 
spheroids would uptake glucose more efficiently than 1k spheroids. Although the LAR is 
lower for the larger microtissue, each 8k adipospheroid likely contains less fat on a per 
cell basis than its 1k counterpart. This can perhaps be most clearly seen in the H&E 
stain of Figure 2-2, where a non-differentiated core was clearly visible in the large 
construct. Furthermore, the per cell production of both Leptin and AdipoQ was lower for 
8k spheroids than for 1k; even if the adipocytes in the 8k spheroid are more sensitive to 
insulin, they are fewer in number (on a per cell basis) than both the 1k and 2D 
conditions. 
To correct for this difference in differentiation efficiency, we discount the non-
differentiated core and assume that only mature adipocytes are responsible for 
observed insulin induced glucose uptake. From our sectioned images, we can estimate 
the non-differentiated core to be about 170 µm in diameter for a 480 µm diameter 
spheroid (Figure 2-5, A). Then, assuming that mature adipocytes increase their 
diameter by 4x compared to preadiopcytes, we calculate the proportion of mature 
adipocytes in an 8k spheroid to be only ~25 percent. Applying this correction to 
observed per cell glucose uptake data gives us a corrected value of 73 pg/cell at 2 
hours, larger than both 1k and 2D conditions and consistent with our LAR data (Figure 
2-5, B). Note that since LAR is expressed as a dimensionless metric, it is unchanged by 
this analysis. 
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2.5 Conclusions 
We successfully cultured spheroids composed of pre-adipocyte cells in hanging 
drop plates and differentiated them into mature fat in situ. Over the course of the 7-day 
differentiation, the adipospheroids increased in both cross sectional area and diameter. 
H&E staining of mature and undifferentiated microtissue revelaed the presence (or 
absence) of lipid vesicles and, in some cases, also showed patterns of heterogeneous 
differentiation across the radius of the spheroid. Adipospheroids were further 
characterized and compared to conventional 2D culture by examining Leptin and 
Adiponectin, two important adipose signaling molecules, secretion by ELISA. We also 
compared the function of these three different types of fat. In the presence of insulin, 1k 
spheroids uptook insulin more efficiently than both 2D and 8k conditions (though 
correcting for any non-differentiated core may be necessary to fully evaluate different-
sized adipospheres against each other). This can be explained by its low leptin-
adiponectin ratio (which indicates comparatively more insulin sensitivity) compared with 
2D and by its greater differentiation efficiency compared to the larger, 8k adipospheroid.  
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Figure 2-1. Adipospheroid size before and after differentiation protocol 
Characterization of adipospheroid formation and differentiation. (A) 1k spheroid 
morphology goes from compact and small at Day 0 (top) to loose and large at Day 7 
(bottom). (B) 8k spheroid morphology goes from compact and small at Day 0 (top) to 
loose and large at Day 7 (bottom). Quantitatively, spheroid size, as measured by (C) 
cross sectional area and (D) perimeter changes significantly over the course of the 
differentiation protocol. Scale bars = 100 µm; data as average ± standard deviation, 
n=3-5; *** indicates p<0.001 by Student’s two-tailed t-test.  
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Figure 2-2. Adipospheroid cross section staining 
Hematoxylin and eosin stain of sectioned adipospheroids at Day 0 (pre-differentiation) 
and Day 7 (mature, post-differentiation). The large vacuoles devoid of H&E staining and 
particularly prevalent in the post-differentiation images are lipid vacuoles. Note the 
change in cell morphology at the spheroid core between the 8k and 1k spheroids. Scale 
bars = 100 µm.  
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Figure 2-3. Comparison of Leptin and Adipoenctin expression of in vitro fat 
(A) Conventional 2D culture secreted far more leptin than 3D adipospheroids over the 
24-hour period starting on day 7 post-differentiation. Note that data is plotted on a log10 
axis. (B) Adiponectin (AdipoQ) production was higher in spheroids compared to fat 
grown in a conventional 2D monolayer. (C) Leptin to AdipoQ ratio is plotted on a log10 
axis. Data reported as average ± standard deviation, n=2-5; *** indicates p<0.001 
versus all other conditions by ANOVA with Tukey post hoc test.  
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Figure 2-4. Insulin-induced glucose uptake by adipospheroids and conventional 
2D culture 
On a per-cell basis, 1k spheroids consumed significantly more glucose than larger (8k) 
spheroids or conventional 2D fat. In general, insulin-induced glucose consumption was 
marked by a rapid jump in the first 10 minutes and then a gradual increase in 
consumption over the remaining 110 minutes. This is consistent the general elevation of 
adipose biomarkers we observe in small, 3D culture. Data reported as average ± 
standard deviation, n=5; ** indicates p<0.01 and *** indicates p<0.001 for 1k (+Ins) 
versus all other conditions by ANOVA with Tukey post hoc test.  
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Figure 2-5. Correcting glucose uptake for undifferentiated core of 8k spheroid 
(A) The larger 8k adipospheroid exhibits an undifferentiated core that does not 
contribute substantially to adipose function. Scale bar = 100 µm. (B) When correcting 
for this core, we find that adipocytes in the 8k spheroid uptake glucose most efficiently, 
in agreement with our LAR data. Data reported as average ± standard deviation, n=5, at 
time t=120 minutes. 
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Chapter 3:  
Experiments to Inform the Design of a Human on a chip System 
Using a 3-Dimensional Fat Model 
Top-down approaches to constructing a microphysiological model of the body must not 
only answer systems-level questions about how different components relate and 
interact, they must also set the terms on which those questions are considered. 
Conventionally, designers select parameters that seem (and likely are) important to 
guide their scaling strategies. Here, we seek explicit experimental support for each 
proposed constraint. Accordingly, we leverage our 3-dimensional, cell-dense model of 
fat tissue to identify key factors in scaling design and suggest how each may be 
important. These experiments identify four specific elements for further scrutiny: First, 
we examine oxygen tension and its effect on cell metabolic activity. Second, we probe 
how drug properties control distribution behavior and observable effects within an HOC. 
Third, we modulate tissue structure and explore its implications for mass transport and 
organ function. Finally, we examine how both relative size of each organ compartment 
and absolute size of the system as a whole are critical design parameters for a robust 
model. Moving forward, these conclusions offer both guidance and explicit support for 
top-down human on a chip design strategies.   
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3.1 Introduction 
In building a microphysiological model of the body (a “human on a chip” or HOC), 
designers must choose or create guidelines to constrain their decisions as they scale 
down over several orders of magnitude. These strategies fall along a continuum 
between “bottom-up” and “top-down.” Bottom-up schemes concern themselves more 
with the disparate parts of the system, rather than the relationships therein, and closely 
related to tissue engineering. Top-down approaches first consider the system-level 
relationship between components of the whole and move forward to fill in the details at 
increasingly finer granularity. We focus on critical questions of size, form, and function 
that arise for top-down designers as they scale over approximately six orders of 
magnitude (1). 
As detailed in §1.2.2, the oldest of these top-down strategies is mass-residence 
time scaling pioneered by Michael Shuler and his research group Cornell University (2–
4). Shuler et al maintain the ratio between compartment (i.e. organ) and system (i.e. 
body) mass and also ensure that tissue resident times – how long the media remains in 
contact with each organ compartment – match those found in the body. Importantly, this 
approach lends itself well to physiologically based pharmacokinetic and 
pharmacodynamic modeling and the researchers demonstrate how such models may 
be used to interpret experimental results – so long as the relevant drug properties are 
known (5–7). Arti Ahluwalia and her research group at the University of Pisa similarly 
focus on organ mass but guide their design using quarter power scaling rules (QPSRs), 
a form of allometric scaling that has been analytically derived and experimentally 
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supported (8–10). QPSRs are examined in further detail in §4.1 and §4.2. Briefly, 
various parameters, like metabolism scale with animal mass, M, raised to the power of 
¾. (The term allometric comes from the Greek αλλος meaning “other” or “different” – 
i.e. an exponent not equal to unity.) Further, Ahluwalia and colleagues scale surface 
area as M2/3, in accordance with the principles of Euclidean geometry (11, 12). 
Recently, however, they have begun to place a greater emphasis on cell number (13). 
John Wikswo of Vanderbilt University relies on a different, entirely empirical form of 
allometric scaling: by inferring relationships between critical organ parameters (e.g. 
heart: volume pumped, lung: gas exchanged) from existing data, his research group 
proposes to design a HOC by extrapolating those relationships over several orders of 
magnitude (14, 15). Finally, Uwe Marx of Technische University in Berlin generally 
advocates scaling by mass, but also with some consideration for organ “functional units” 
and pharmacokinetic parameters such as absorption, distribution, metabolism, and 
excretion (16, 17). 
To be sure, these approaches are all rooted in logic. The way in which each 
strategy identifies key parameters, however, can be more difficult to see. By intuition, 
most, if not all, of these factors appear significant. Nevertheless, we seek to provide 
experimental support for considering and controlling certain aspects of an HOC. To that 
end, we use our adipospheroids to demonstrate how four parameters – oxygen level, 
drug distribution, tissue size, and tissue structure – that seem important actually are 
important. From these data, we formulate several rules to aid in the design of a feasible, 
physiologically-relevant HOC. 
  38 
3.2 Oxygen level impacts insulin response 
Molecular oxygen is fundamental to animal life. Its most important role is perhaps 
as an oxidizing agent in the electron transport chain that lies at the heart of respiration 
and drives both cellular and systemic metabolism in aerobic organisms (18, 19). Thus, a 
rational consideration of oxygen level is fundamental to a physiologically relevant HOC. 
To investigate how varying oxygen tension may affect tissue in vitro, we again examine 
insulin-mediated glucose uptake of 3D multicellular fat spheroids. Conveniently, 
adipospheriods grown in hanging drop plates represent an excellent opportunity to test 
whether oxygen tension is an important consideration in designing an HOC. Because of 
the high droplet surface area and low volume, hanging drop (HD) culture offers superior 
gas exchange properties (unpublished data). Adipospheroids containing 8k 
cells/spheroid were cultured to maturity as described in §2.2. At day 7 post 
differentiation, half of the spheroids were transferred to an oxygen-controlled incubator 
and cultured in a 2 percent oxygen atmosphere, typical of the body, for another four 
days (Lo O2). The remaining spheroids were cultured in 20 percent oxygen (Hi O2), 
typical of laboratory incubator cell culture. Media for both sets of spheroids was 
changed at day 9 post-differentiation.  
On the day of the experiment (day 11 post-differentiation), all spheroids were 
insulin starved for 3 hours in HBSS with 0.5 mM glucose and divalent cations (HBSS-g). 
Over the four extra days of culture, lipid accumulation continued in both lo and hi O2 
adipospheroids. As a result, many of these “fatter” tissue constructs floated, making 
retrieval by conventional means difficult once the spheroids were harvested from the HD 
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plates. To address this, we pipetted the adipospheroid-containing solution directly onto 
discs of filter paper (Fisher Scientific) cut to 10 mm in diameter. The filter paper allowed 
excess media to wick through to a paper towel placed below specifically for this 
purpose. Adipospheroids, however, remained on the filter paper so long as care was 
taken to pipette gently. To conduct the glucose uptake assay, filter paper discs 
containing 50 spheroids each were added to glass vials filled with 272 µL HBSS-g. At 
t=0-, all conditions were sampled by removing 2 µL of media with a pipette. 
Subsequently (t=0+), HBSS-g with insulin was added to bring the total volume of each 
experiment to 300 µL at a concentration of 10 µg/mL insulin. A vehicle dose was added 
to bring the HCL concentration of each control (no insulin) condition to 0.05 mM HCl to 
account for acid in the insulin stock solution. All samples were then placed in an 
incubator at 20 percent oxygen, gently agitated, and sampled at t = 10, 30, 60, and 120 
minutes. Supernatant glucose levels were determined as described in §2.4.1 and are 
reported as cumulative glucose uptake per cell. Data was analyzed for statistical 
significance using ANOVA and Tukey’s post hoc test at confidence level α=0.05 (Figure 
2-1).  
Although no conditions achieved significance by this metric, two timepoints (t=60 
and t=120) did show p-values < 0.1 when comparing hi and lo O2 insulin-containing 
conditions. A more aggressive analysis of the data, however, may apply Fisher’s Least 
Significant Difference test. Typically, staticians avoid this test because it fails to correct 
for multiple comparisons (resulting in a higher rate of false positives). Like Tukey, it 
pools variances to increase power – especially important in this case where we have 
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few replicates (in some cases as low as n=3). Using Fisher’s post hoc test, we report p-
values of <0.05 for both t=60 and t=120 and denote them with a “+” sign. 
Surprisingly, the data indicate that low oxygen actually increased fat activity (here 
measured by Glut4-mediated glucose uptake). Typically, low oxygen tends to suppress 
cellular basal metabolic rate (20). By extension, we would assume glucose uptake 
activity of adipocytes would similarly decrease. However, Glut4 is a passive transporter 
of glucose and therefore unlikely to be affected by subtle changes in cell metabolism, at 
least over short time periods (21). Furthermore, other researchers have demonstrated 
that oxidative stress has a similar effect on 3T3-L1 cells in vitro (22, 23). Recently, a 
clinical study observed and explored this same phenomenon in vivo, concluding that 
oxidative stress was capable of interfering with Glut4 glucose uptake and was chiefly 
responsible for the early onset of insulin resistance in patients placed on a high calorie 
diet (24). Although these results are unexpected, they are explained by the literature. 
More importantly – as the oxygen tension in vitro can differ from the body by a factor of 
up to ten (25) – they further highlight the need for careful consideration of the oxygen 
tension in any HOC. 
3.3 Volume of distribution is an important consideration for drug toxicity studies 
The way a drug spreads throughout the body and which tissues it partitions to at 
equilibrium are key considerations for pharmacologists. Collectively, these properties 
are called distribution and quantified by a “volume of distribution” measurement 
describing how much liquid the drug appears to be dissolved in, given the initial dose 
and the concentration in the blood according to Equation 3-1: 
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𝑉" = 	𝐷𝑜𝑠𝑒 𝐶* 
Equation 3-1 
where VD is the volume distribution, Dose is the total amount of drug administered, and 
CB is the concentration of drug in the blood. VD has units of volume and, at its most 
basic level, describes whether a drug prefers body water (and thus is more hydrophilic) 
or body tissue (and thus is more hydrophobic). Accordingly, VD provides valuable 
information about how a drug behaves as it is administered, while in the body, and as it 
leaves (26, 27). 
 To assess how the inclusion of different tissues might affect drug distribution in 
an HOC, we constructed a simple distribution experiment to study how fat (or any other 
tissue) might modulate liver cell toxicity in the presence of amiodarone. An extremely 
hydrophobic drug, amiodarone is a WHO essential medicine commonly used to treat 
arrhythmias, but is also known to cause a variety of organ toxicities in vivo (28–30). 
HepG2-C3A cells (ATCC) were grown in DMEM with 10 percent FBS and 1 percent 
anti/anti and plated at 35k cells/well in a 96-well plated night before the experiment. Fat 
spheroids (8k cells/spheroid) were prepared as described in §2.2 so that they reached 
maturity (culture day 7) on the day of the experiment. The day of the experiment, 
adipospheriods were counted, harvested, and placed in wells containing a liver cell 
monolayer as 0, 1, 10, or 30 spheroids. Amiodarone (carried in DMSO) was added to 
designated wells at 0, 1, 10, and 100 µM and DMSO levels were kept constant at 
1/1,000 (v/v) across all conditions. After 24 hours, the spheroids were rinsed away and 
cell metabolic activity was assayed by incubating cells with AlamarBlue (LifeTech) over 
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2 hours. In the presence of cellular respiration, non-fluorescent AlamarBlue is reduced 
to a fluorescent molecule and measured using a plate reader (BioTek Synergy Neo) at 
excitation and emission wavelengths of 560 nm and 590 nm, respectively. 
Subsequently, cell viability was measured using a CellTiterGlo (Promega) kit to assess 
cellular ATP levels. In both cases, values are normalized to the 0 µM amiodarone dose 
condition. Critical to the success of this experiment, differentiated fat is non-adherent – 
meaning there was no observable migration of cells from the spheroid to the plate. 
Experiments conducted with other spheroids types were frustrated by heavy cell 
migration or, in some cases, entire spheroids anchoring onto the monolayer, hopelessly 
confounding viability and metabolic activity measurements (data not shown). 
 These experiments show that, at sufficiently lethal doses of amiodarone, 
adipospheriods protected liver cell viability and metabolism, likely by sequestering the 
hydrophobic drug themselves. Measurements of both metabolic activity (Figure 3-2, A) 
and cell viability (Figure 3-2, B) indicated that the presence of adipospheriods 
significantly shielded liver cells from amiodarone toxicity (* p<0.05, ** p<0.01, *** 
p<0.001 by ANOVA with Tukey post hoc test). Although expected, these results 
highlight the importance  of taking pharmacokinetic concepts (such as volume 
distribution) into consideration when designing an HOC. For example, the liver cells in 
each well have a mass of ~70 µg and a surface area of 32 mm2 , both corresponding to 
the liver of a ~4x10-8 scale human. Applying this same scaling factor to the drug 
concentration reveals that the 100 µM amiodarone condition from our experiment falls 
within an order of magnitude of the range of clinical amiodarone doses as well (up to 
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~10 mmol). Without considering volume distribution effects, we would advise doctors to 
never administer this drug as substantial toxicity appears to result from clinical doses 
administered to the liver cells alone. However, the 10 and 30 adipospheroid conditions 
(which have 1/6 and 1/2 the fat we would expect for a ~4x10-8 human, respectively) 
shows substantially reduced toxicity and indicates that patient toxicity is likely to differ 
from our observations in vitro. Indeed, including even more tissue mass (e.g. the full 
amount of adipose tissue or a separate muscle tissue construct) would likely further 
restore liver metabolic function and viability. Accordingly, we conclude that our HOC 
must consider the impact of drug distribution behavior on relevant parameters such 
media concentration level of a given drug or metabolite. 
3.4 Tissue geometry affects compartment function 
Within the body, fat is anything but passive. Adipose tissue is a critical regulator 
of metabolism and nutrient supply as well as an important source of regulatory 
hormones such as Adiponectin and Leptin (31). In states of hyper- or hypoglycemia, fat 
is also charged with sequestering or mobilizing energy. In the case of the former, 
adipose cells respond to insulin by uptaking glucose from the blood via the Glut4 
transporter (32). In any HOC, fat would play a crucial role in system homeostasis and 
should therefore be scaled appropriately. Accordingly, we leverage our adipospheriod 
cell constructs as a proxy to test whether size and structure are indeed important 
considerations for designing an HOC system. Intuitively, both considerations should be 
important, but we seek explicit confirmation. 
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3.4.1 Probing organ size and structure 
In order to carry out experiments with a reasonable number of cells and maintain 
relevant cell-media volume ratios, we choose to use a simple microfluidic device to 
probe insulin-mediated glucose uptake by mature adipospheroids. The microfluidic 
chips used for all experiments consisted of 0.1 mm tall by 1 mm wide inlet and outlet 
channels connected to an open 3mm-diameter chamber (Figure 3-3, A&B). Microfluidic 
channels were fabricated using conventional soft lithography. Briefly, a mold was 
produced using SU-8 (Microchem) photolithography on silicon wafers, using protocols 
described by the manufacturers. Poly(dimethylsiloxane) (PDMS) base and curing agent 
(Sylgard 184, Dow Corning) were mixed in a 10:1 ratio by weight, degassed, and 
poured over the SU-8 mold. After curing at 60 °C overnight, the PDMS channels were 
cut, and a 3mm biopsy punch was used to core out the central chamber. The PDMS 
device was then bonded to glass slides using a plasma cleaner (Covance MP-1, Femto 
Science), and placed in a 120 °C oven to increase bonding strength and decrease 
hydrophilicity of the treated device.  
To run an insulin-mediated glucose uptake assay, the central chamber was filled 
with a collagen gel containing either intact or dispersed adipogenically differentiated 
spheroids. 64k spheroids (Figure 3-4, A) were dispersed by incubating in a solution of 
10 μg/mL collagenase IV (Worthington Biochemical) in phenol red-free DMEM (Life 
Technologies) at 37 °C for 5-10 minutes and manually repeat pipetted. A Live/Dead Cell 
Viability Kit (LifeTech) showed minimal cell death resulting from the dispersion protocol 
(Figure 3-4, B). Dispersed or whole spheroids were resuspended in 20 μL collagen gel 
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precursor solution, loaded into the central chamber with a pipette, and allowed to gel for 
15 minutes at 37 °C. An array of 100 μm side-length posts similar to those described by 
Jeon and colleagues was designed to keep the cell-laden hydrogel precursors from 
flowing into either the inlet or outlet channels (33). To form the collagen gel precursor 
solution, 500 μL type I bovine collagen (BD Biosciences) was mixed with 60 μL 10x 
phosphate buffered saline, and 50 μL 0.8 M NaHCO3 and kept on ice until ready for 
use. A PDMS slab was then used to seal the chamber for flow experiments. The chip 
was perfused with high glucose phenol red-free DMEM containing 10 μg/mL insulin at a 
constant flow rate of 1 μL/min. After 15 minutes of flow, 10 μL of perfusate was 
collected and stored on ice for later analysis. In order to improve sample collection, 
device dead volume was minimized. Before loading the central chamber, the device 
was primed by bringing the insulin/DMEM solution to the edge of the chamber. 
Moreover, the outlet channel only had a volume of 0.5 μL (1x0.1x5 mm). Although there 
remained ~4 μL of dead space in the collagen gel matrix, there was sufficient volume of 
perfusate available for collection at the end of the experiment. Glucose levels in 
perfusate were measured using an Amplex Red Glucose Oxidase Assay Kit (LifeTech). 
Outliers were identified and discarded according to Pierce’s test (34) and data was 
analyzed for statistical significance using two-way ANOVA with Tukey’s post hoc test. 
To test the hypothesis that relative organ size is a critical consideration for a 
high-fidelity microfluidic model of the body, we used this microfluidic setup to examine a 
2-organ (blood, fat) HOC system. Mature, dispersed adiposheroids were seeded in the 
tissue chamber in either 10x (192k cells) or 1x (19.2k cells) cell concentrations while the 
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media perfusion (i.e. the “blood” volume) was held constant. The 10x condition is 
consistent with a ~x10-7 volumetrically-scaled fat compartment while the 1x condition 
represents a case where the scaling is off by an order of magnitude. In control 
experiments, without insulin, there is no discernable change in glucose levels of the 
perfusate between the two conditions. Upon the addition of insulin, however, the 10x fat 
compartment uptakes ~5x more glucose than the 1x compartment (p<0.001), which 
remained near control levels (Figure 3-5). The glucose uptake by cells in the 10x 
condition agreed with previous reports of insulin-induced glucose uptake by adipocytes 
(35, 36). Glucose levels leaving the adipose chamber were substantially different 
depending on the scaling approach. As part of an integrated, multi-organ system, any 
imbalance in media glucose levels could have significant effects for other aspects of the 
HOC. We not only demonstrate this important design criterion for fat, but also argue that 
it holds across other organs as well. Therefore, this data highlights the importance of 
choosing HOC organ sizes that are correctly scaled relative to each other and relative to 
the system as a whole (37). Since these experiments, others have arrived at similar 
conclusions, albeit by different approaches (13). 
The unique structure of our adipospheroids also provided us a convenient 
platform to test the hypothesis that the structure of a tissue, in addition to its size, is a 
critical consideration when designing an HOC. For this experiment, three 64k spheroids 
(192k cells, same as 10x condition above) were placed in the microfluidic chamber in 
either a dispersed configuration as before or wholly intact. Again, control (no insulin) 
experiments failed to demonstrate any meaningful difference between tissue structures, 
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but upon insulin stimulation, the dispersed condition consumed significantly more 
glucose (p<0.01, Figure 3-6). The difference is likely due at least in part to 
transportation limitations, but this data nevertheless emphasizes that HOC designers 
must consider in vivo organ structure when designing in vitro mimics, especially as part 
of an integrative system. We propose that identifying whether the critical function of 
each organ is associated with surface area or volume and scaling accordingly is one 
strategy that can address these concerns. This “functional” scaling will be discussed in 
greater detail in §4.5.1. 
3.4.2 Selecting an appropriate HOC scale 
In addition to considering the relative sizes of an HOC, we must also consider 
size in an absolute sense. To do this, we conduct a brief parameter sweep across 
several different miniaturization factors, examining implications for the lung, a primarily 
2-dimensional organ, and fat, a primarily 3-dimensional organ (Table 3-1). In 
accordance with QPSRs, blood volume is scaled linearly with mass (9). In scaling the 
lung, we seek to maintain surface area and physiologic shear stress while accounting 
for the M3/4 change in cardiac output (9, 37–40). Accordingly, 2D organ compartment 
dimensions are chosen to provide the most realistic culture space and shear stress is 
calculated according to Equation 3-2: 
𝜏 = 	6𝜇𝑄𝑤ℎ1 
Equation 3-2 
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where τ = shear stress, µ = viscosity, Q = flow rate, w = chamber width, and h = 
chamber height (37). Fat mass is simply scaled linearly with body mass and cell number 
calculated by assuming an cell mass of ~1 ng (39, 41, 42). 
 Table 3-1 reveals key insights about what scale of HOC is most feasible. The 
x10-7 size boasts attractive compartment dimensions for the lung that are easily 
obtained with conventional microfluidic fabrication techniques, but has a blood volume 
of 600 nL, quite small for an entire HOC system, even using microfluidic tools. For 
example, assuming a channel height of 40 µm and channel width of 100 µm, we would 
have only 150 mm of length along which to fit all relevant organs! Meanwhile a x10-4 
scale offers an attractive blood volume, but requires a lung compartment with 70 cm2 of 
surface area – well outside the capabilities of conventional fabrication tools. Moreover, 
the x10-4 fat compartment requires billions of cells which again strains current 
capabilities. At a x10-6 miniaturization factor, surface areas, blood volumes, and cell 
numbers all appears somewhat manageable. Thus we proceed with the design of our 
HOC at a scale of x10-6 compared to a full-sized human. 
3.5 Conclusions 
In this chapter, we attempt use the adipospheroids developed previously to 
establish a framework for key details to consider when designing a microphysiological 
model system of the human body (an HOC). By culturing fat spheroids in different 
oxygen environments, we showed that oxygen plays a vital role in cell metabolism. A 
brief study of amiodarone toxicity to liver showed that a realistic distribution space, in 
addition to appropriate inter-organ relationships, is a key scaling consideration. Lastly, 
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we explored both relative and absolute sizing. The unique, 3D structure of these 
spheroids allowed us to interrogate how size and structure may affect inter-organ 
crosstalk and a parameter sweep of lung, blood, and fat compartments indicated that a 
x10-6 scale would be an appropriate miniaturization factor. These exercises all 
demonstrated key functional properties of these adipospheriods, but more importantly 
identified oxygen tension, drug distribution, and tissue size/structure as key design 
considerations warranting further scrutiny. Moving forward, we build on the principles 
established in this chapter to move towards a physiologically relevant HOC.  
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Figure 3-1: Culture oxygen level affects insulin-induced glucose uptake among 8k 
adipospheroids. 
Mature adiposhperiods grown in either high (Hi; 20 percent, typical of laboratory 
incubator culture) or low (Lo; 2 percent, approximating oxygen tension in the body) 
oxygen conditions were stimulated with insulin and cumulative glucose uptake was 
measured over two hours. Under these conditions, adipospheroids grown at low oxygen 
levels demonstrated more efficient glucose uptake. Data reported as average ± 
standard deviation, n=3-5; + indicates p<0.1 by ANOVA with Tukey post hoc test.  
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Figure 3-2. Adipose spheroids rescue liver cells from amiodarone toxicity 
HepG2-C3A cells cultured in the presence of amiodarone showed a marked decreased 
in both (A) metabolic activity and (B) viability at high doses of the drug. Co-culture with 
mature adipospheroids abrogated these effects, especially culture with 10 or 30 fat 
spheroids (a number approximating the liver-adipose mass ratio in a healthy adult). 
Data reported as average ± standard deviation; n=3-4; * indicates p<0.05, ** indicates 
p<0.01, and *** indicates p<0.001 by ANOVA with Tukey post hoc test.  
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Figure 3-3. Experimental setup for insulin-mediated glucose uptake experiments 
Two-compartment organ-on-a-chip devices. (A, B) Schematics demonstrating device 
structure and operation. Cell- or spheroid-laden collagen is gelled in the collagen 
chamber. The posts around the chamber prevent the collagen from travelling into the 
channels. A syringe pump forces media through the system at a volumetric flow rate Q 
of 1 µL/s, and the pooled perfusate is pipetted away at the end of the experiment.  
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Figure 3-4. Adiposheroids containing 64k cells each were used to mimic fat 
Tissue structure was manipulated by either (A) leaving the spheroid intact or (B) 
dispersing the spheroid with collagenase and gentle mechanical aspiration. After the 
dissociation process most cells remained viable as indicated by live/dead staining 
(green = calcein AM stained cells, live; red = ethidium homodimer stained cells, dead). 
Scale bars = 300 µm.  
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Figure 3-5. Effect of tissue size on glucose uptake 
Tissue size (i.e. number of dispersed cells) significantly affects cumulative insulin-
stimulated glucose uptake for a microfluidic model of fat. 10x condition corresponds to 
cells from 3 dispersed spheroids (approximately 192k cells) while 1x condition 
corresponds to approximately 19.2k cells. Data plotted as average ± standard deviation 
for n=7-8 with outliers identified and excluded by Pierce’s test. *** indicates statistically 
significant against all other conditions by two-way ANOVA and Tukey post hoc test with 
p<0.001.  
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Figure 3-6. Effect of tissue structure on glucose uptake 
Tissue structure (i.e. intact or dispersed spheroid) significantly affects cumulative 
insulin-stimulated glucose uptake for a microfluidic model of fat. Dispersed condition 
consists of cells from three 64k adipospheroids dissociated by collagenase and 
mechanical aspiration. Data plotted as average ± standard deviation for n=7-8 with 
outliers identified and excluded by Pierce’s test. ** indicates statistically significant 
against all other conditions by two-way ANOVA and Tukey post hoc test with p<0.01.  
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Scale Blood volumeα 
Lung Fat 
Dimensionsβ 
Volume % BV Massγ Cell numberδ Length Width Height 
Humanε 6 L --- --- --- --- --- 23 kg 2x1013 
x10-4 600 µL 1 cm 70 cm 25 µm 175 µL 35 2.3 g 2x109 
x10-6 6 µL 9 mm 8 mm 35 µm 2.5 µL 42 23 mg 2x107 
x10-7 600 nL 5 mm 1 mm 35 µm 175 nL 30 2.3 mg 2x106 
 
Table 3-1. Key design values for lung and fat at different miniaturization factors 
To determine an appropriate absolute system size, we examine critical parameters for 
prototypical 2-dimensional (lung) and 3-dimensional (fat) organs across three 
miniaturization factors. Considering the challenges presented by small blood volumes, 
large surface areas, and total cell numbers, we conclude that x10-6 is the most 
convenient scaling factor for constructing a microfluidic human on a chip. 
 
α – According to QPSRs, blood volume scales with M1 (9). 
β - Lung dimensions are chosen to match physiologic shear values given cardiac output 
at the chosen scale. Shear is calculated according to the Equation 3-2 (37). 
γ – Organ mass is scaled according to M1. 
δ – Assuming a cell mass of 1 ng/cell (42). 
ε – Human values derived from several sources (38–41). 
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Chapter 4:  
Building an Experimental Model of the Human Body with Non-
Physiological Parameters 
New advances in engineering and biomedical technology have enabled recent efforts to 
capture essential aspects of human physiology in microscale, in vitro systems. The 
application of these advances to experimentally model complex processes in an 
integrated platform – commonly called a “human on a chip” (HOC) – requires that 
relevant compartments and parameters be sized correctly relative to each other and the 
entire system. Empirical observation, theoretical treatments of resource distribution 
systems, and natural experiments can all be used to inform ration design of such a 
system, but technical and fundamental challenges (e.g. small system blood volumes 
and context-dependent cell metabolism, respectively) pose substantial, unaddressed 
obstacles. Here, we develop a holistic, nature-inspired approach to these problems, 
demonstrating that O2 deprivation is a viable strategy for inducing in vivo-like cellular 
metabolic rates in vitro and that the effects on increased blood volumes on drug 
concentration can be mitigated. Combining these principles, observations, and 
strategies, we derive a basic set of design criteria for a practically-realizable, 
physiologically-faithful, five-organ x10-6 microfluidic model of the human body.  
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4.1 Introduction 
Advances in micro-scale engineering, cell sourcing, and culture techniques are 
presenting new opportunities to recapitulate key structural and functional characteristics 
of the human body in controlled, in vitro, experimental systems. Already, organ-level 
devices (commonly called “organs-on-a-chip” or OOCs) are quite prolific (1–3). Efforts 
at devising systems-level platforms (“humans-on-a-chip” or HOCs) hold even greater 
promise (4–7). Ideally, these small HOCs would predict the effects of potential drugs or 
toxins will have on the human body (8–10), significantly reducing costs associated with 
animal and human clinical trials in the drug discovery pipeline and clarifying 
mechanisms of human health and disease. However, unresolved issues in both the 
design and fabrication of such systems present scientists and engineers with a 
complex, interconnected set of problems.  
Nutrient distribution networks (specifically those for oxygen) generally control the 
relationship between organism size and metabolism (11–13). As a result, many 
important physical parameters scale with organism mass (M) raised to the power of a 
multiple of ¼, called quarter-power scaling relationships (QPSRs) for short (e.g. 
metabolic rate: M¾, heart rate: M-¼, and blood volume: M1). These QPSRs (6, 14, 15), 
along with simple heuristics (16, 17), residence time and PB-PKPD models (4, 5, 8, 18–
20), empirical allometry (21, 22), and functional approaches (21–23) have also been 
used in the design of HOCs. Although these approaches do inform values for organ 
compartment size and other physiological parameters, they also present intractable 
problems. Some issues that arise, such as context-dependent changes in cellular BMR 
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(24–27), are fundamental and may only be remedied by careful and deliberate design. 
Others, such as difficult to fabricate, low total blood volumes for a x10-6 HOC (2, 7, 17, 
20, 21), are technical and may be overcome with suitable advances in science and 
engineering.  
We propose that these challenges themselves only merit concern so far as they 
affect the end output of the HOC. That is, the structure of a x10-6 HOC may assume 
strange and unexpected forms so long as the function – the system-level behavior of 
the HOC – is accurate and relatable to the human body. Therefore, discrete parts of an 
HOC need not be confined by conventional notions of what constitutes “normal” or 
“physiologic” even if those values are prescribed by well-supported research such as 
QPSRs. To that end, we focus on designing and x10-6 HOC capable of mimicking key 
functions of a macro human: (1) cellular and macro basal metabolic rates and (2) basic 
pharmacokinetics. We further demonstrate how Nature herself may stray from 
structures of typical physiology (e.g. a hemoglobin-free vertebrate), yet produce species 
capable of adapting and surviving. As modification of any one system parameter 
necessarily affects all others, both natural and artificial design alterations demand a 
holistic approach. Applying these general principles, we propose specific design 
parameters for an HOC that is practical in terms of fluid to cell ratios and is a x10-6 
miniaturization of the human body with regards to total cell mass, yet remains a faithful 
model of macroscopic human physiology with regards to cellular BMR, basic 
pharmacokinetics, and inter-organ scaling. 
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4.2 Control of cellular BMR 
As predicted by QPSRs, cellular metabolic rate scales with animal mass (24, 25, 
27). However, cells cultured in vitro tend to operate at the same, elevated metabolic rate 
regardless of their origins (Figure 4-1, A) (24, 26). Without accounting for this 
phenomenon, cells in an HOC would have a high BMR, more akin to cells in mouse 
(Figure 4-1, B) than in a human (Figure 4-1, C). As a result, the total BMR of the 
modeled organism diverges from that observed in nature; the magnitude of the error 
increases with organism size as ∝M¼ (Figure 4-1, D). For example, failure to consider 
the context-dependent behavior of cells in attempting to design a x10-6 model of a 
human would result in an HOC wherein the cellular BMR is high and thus approximates 
that of a mouse and the system BMR is also high and approximates that of a x10-6 
elephant! Because of this non-linearity in scaling, rational design – and control – of the 
metabolic infrastructure of an HOC is crucial. We propose that designers must force 
cells in an HOC to function as they would in the body – that is, designers must suppress 
cellular BMR in accordance with Figure 4-1, A. Accordingly, we dub this principle 
“metabolically-supported” scaling. An interesting consequence of this strategy is that, by 
virtue of holding cell BMR constant, it abolishes the M¾ dependence of system BMR, 
instead replacing it with a M1 dependence and causing the relationship between human 
and HOC BMR to lie on a fundamentally different trajectory than human-animal (Figure 
4-2). 
Although others have demonstrated metabolic control by regulating glucose (28), 
ions (29), or ECM cues (30), we propose to suppress cellular BMR by regulating oxygen 
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(23). Not only does this approach more closely approximate conditions in the body than 
the hyperoxic conditions of incubator cell culture, but in situ microfluidic O2 sensing and 
control is an established and active area of research (31–33). We attempt, with three 
different experimental techniques, to demonstrate this effect. Although we are 
unsuccessful here, we note that others have observed a ~2.5 fold decrease in cellular 
oxygen consumption when cells are subjected to in vivo-like oxygen tension (34).  
4.2.1 Extracellular flux analysis 
To demonstrate that O2 deprivation is a viable method for controlling cellular 
metabolic rate, we examine the behavior of five human cell types in a Seahorse XFe 
Extracellular Flux Analyzer: IMR-90, a lung fibroblast cell line; HepG2-C3A, a liver 
carcinoma cell line; NHBE, primary normal bronchial epithelial cells; NHA, primary 
astrocytes; and HCMEC, primary brain endothelial cells. The XFe Analyzer creates a 
microchamber around the cells and monitors O2 and pH levels over time (Figure 4-2, A). 
Accordingly, our hypothesis was that as cells depleted environmental O2, we would be 
able to observe a corresponding decrease in BMR 
HEK-293, HS-5, HepG2-C3A, and IMR-90 (ATCC) cells were grown in DMEM 
supplemented with 10% FBS and 1% antibiotic-antimycotic. NHBE cells (Lonza) were 
cultured using BEGM BulletKit media (Lonza), NHA cells (Lonza) were cultured in ABM 
BulletKit media (Lonza), and HCMEC cells (Cedarlane Labs) were cultured in EBM-2 
BulletKit media (Lonza). The night before the experiment, cells were trypsinized, 
counted, resuspended, and plated in a 96-well assay microplate. A second, identical 
microplate was seeded for cell quantification. The same assay media was used for all 
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cell types and consisted of Seahorse Base Medium (Seahorse Bioscience), 
supplemented with 4.5 g/L D-glucose, 110 mg/L sodium pyruvate, and 54 mg/L L-
glutamine. Before use, the pH was adjusted to 7.4 ± 0.05. The morning of the 
experiment, the assay plate was washed three times with assay media and placed in a 
CO2-free incubator. After 1 hour, the assay plate was washed twice more and the 
experiment begun. The XFe Analyzer forms a 2.12 µL microchamber around the cells 
and monitors pH and O2 levels over the course of an hour.  
The rates of change of these measurements are then computed using an 
algorithm to account for the gas permeability of the plate and diffusion into and out of 
the chamber (35). We calculate BMR using the known stoichiometry between O2 
consumption, H+ production, and ATP production (36). BMR is normalized according to 
the number of cells per well as determined by CellTiter-Glo (Promega) on the 
quantification plate. Since oxygen depletion in the microchamber is driven solely by the 
cells, only one condition reached in vivo organ O2 levels (37) over the course of the 
hour-long experiment (Figure 4-3, B). Therefore, we conclude that cellular activity alone 
is not sufficient to drive the necessary microchamber oxygen depletion over the course 
of the hour-long experiment and search out an alternative method to test our 
hypothesis. 
4.2.2 Glucose and lactate measurements 
Since the cells alone were incapable of driving sufficient oxygen depletion, we 
used an atmosphere control system to impose different oxygen tensions on cellsand 
sought to determine cell BMR by measuring glucose uptake. Using the same setup as 
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in §4.2.3, we exposed HEK-293, IMR-90, HS-5, and HepG2-C3A cells to 2, 7, and 20 
percent oxygen for a total of 24 hours. As suggested by a previous report (34), the 2 
and 7 percent O2 conditions were gradually drawn down from atmospheric oxygen over 
the course of four hours. At the end of the experiment, media samples were collected 
and glucose levels were measured as described in §2.4.1. Subsequently, a CellTiterGlo 
(Promega) kit was used to assay ATP levels of the cells. 
With some conditions characterized by large error bars, the glucose 
measurements showed that cellular uptake increased with decreasing oxygen tension 
(Figure 4-4, A). This data, however, is confounded by two issues. First, cells may use 
glucose to produce energy either by aerobic respiration or via glycolysis/fermentation 
(36, 38). As cells shift to glycolytic/fermentation pathways, increased glucose uptake 
could still result in an overall decrease in cellular BMR. We attempted to tease out this 
effect by assaying for lactate in our samples, however a lactate detection kit (Sigma) 
provided inconsistent results, with internal controls giving different values. Second, 
glucose uptake does not necessary correspond to glucose usage. For example, liver 
cells, including the HepG2 line used here, also uptake glucose to synthesize glycogen, 
storing nutrients for later use (38–40). ATP levels showed a more expected trend, with 
ATP content per cell decreasing significantly with decreasing oxygen availability (Figure 
4-4, B). At the very least, this indicates that cell reduce their energy reserves under low 
oxygen tension conditions and agrees with previous results (34). 
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4.2.3 Metabolic reduction indicator 
Finally, we used the same oxygen control system and used AlamarBlue, a 
metabolic indicator, to look for evidence of oxygen conformance. HEK-293, IMR-90, HS-
5, and HepG2-C3A cells were seeded at 25k cells/well in 96 well plates and allowed to 
adhere overnight. The plates were then placed in an atmosphere control chamber 
(BioSphyrix OxyCycler, New York) within an incubator and set to 2, 8, or 20 percent 
oxygen with 5 percent CO2. Each condition was allowed to equilibrate in the controlled 
atmosphere for 4 hours at which point AlamarBlue (LifeTech), an indicator of metabolic 
activity, was added. Two hours later, the fluorescence of each plate (proportional to the 
amount of reduced AlamarBlue) was measured on a fluorescent plate reader (BioTek) 
at 560/590 nm (ex/em). Surprisingly, the results indicated that AlamarBlue metabolism 
actually increased in low oxygen conditions (Figure 4-5, A) – the opposite of what we 
had expected. 
Initially, we hypothesized that AlamarBlue may be subject to re-oxidation. A more 
oxygen-rich environment would then lead to less reduced (fluorescent) AlamarBlue in 
solution. We tested this suspicion by fully reducing AlamarBlue solution in an autoclave 
according to manufacturer instructions, incubating the solution at oxygen tensions of 2, 
7, and 20 percent, and measuring the fluorescence after two hours. The data showed 
no measurable change in fluorescence (Figure 4-5, B), indicating that oxygen tension 
does not influence the AlamarBlue signal itself.  
However, if we scrutinize the mechanism by which AlamarBlue is reduced and 
becomes fluorescent, an important consideration emerges. AlamarBlue indicates cell 
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metabolic activity by serving as an electron acceptor during aerobic respiration. It has a 
strongly positive oxidation reduction potential value compared to other relevant 
biomolecules (e.g. cytochrome c) meaning that it is more likely to serve as an oxidizing 
agent. Nevertheless, this value is still nearly three times less than that of oxygen. As a 
result, changing the oxygen availability across different conditions will necessarily 
change how well AlamarBlue is able to compete to accept electrons – the two 
parameters are thus convoluted and changing O2 levels must be controlled for. 
To account for the affect of changing oxygen tension on AlamarBlue reduction, 
we use Equation 4-1 to account for the reduction potential of both molecular oxygen and 
AlamarBlue in the face of changing oxygen level: 
𝐵𝑀𝑅 = 𝐴𝐵678 ∗ ∆𝑃<* + 𝑋 ∗ ∆𝑃?1∆𝑃<*  
Equation 4-1 
where ABRed is the fluorescent measurement from the assay, ∆PAB is the difference in 
reduction potential between AlamarBlue and cytochrome c, the ultimate reducing agent 
of oxygen in aerobic respiration, X is the fractional reduction of oxygen tension 
compared to a 20 percent O2 atmosphere, typical for a laboratory cell culture incubator, 
and ∆PO2 is the difference in reduction potential between O2 and cytochrome C. Using 
values standard values to calculate ∆P (41), we can generate a corrected BMR. 
Although this metric is unitless, we may nevertheless compare relative BMR’s ( 
Figure 4-6). With this new dataset, we see that all four cell types do indeed respond to 
lower oxygen levels by decreasing cellular BMR, validating our approach. Two caveats 
must apply to this analysis, however. First, the BMR values compared here are aerobic 
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only; we make no effort to measure energy derived from fermentation. As respiration is 
an order of magnitude more efficient, any error introduced by this approach is likely to 
be sufficiently small. Second, while these BMR’s are purely relative measurements, one 
may theoretically use a series of calibration experiments to arrive at a set of absolute 
measurements for cellular metabolic rates by this method. 
4.3 An example of extra-physiologic survival – the icefish 
The design modifications proposed in §4.2 beg the question of whether such 
extreme departures from expected physiologic parameter values are acceptable. Would 
an organism with drastically altered blood O2 carrying capacity or completely lacking Hb 
be viable at all? Fortunately Nature herself has provided a unique example of such 
extra-physiologic adaptation and survival. The family Channichthyidae (sometimes 
called “icefish”) comprises hemoglobin-negative (Hb-) fish living in the Antarctic waters 
of the Southern Ocean. First documented in the 1840’s, initial attempts to examine the 
fish were thwarted by an uncooperative cat who absconded with the specimen before it 
could be further studied (42). Subsequent investigations highlighted family members’, 
including Chaenocephalus aceratus’s (Figure 4-7, A) startling lack of blood pigment and 
hemoglobin (Figure 4-7, B) (43–46). Just as technical and fundamental limitations force 
HOC designers to contort system parameters in strange or unexpected ways, so too 
has Nature forced C. aceratus to counter its own maladaptation in order to survive.  
To demonstrate, and perhaps learn from, this extra-physiologic survival, we 
examine the fish in more detail. As a control, we use a cousin of C. aceratus, N. 
coriiceps (also called neglecta), from the common suborder Nototheniodei (47). N. 
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coriiceps shares a similar environment and metabolic rate (measured by oxygen 
consumption) as C. aceratus (48–50), but unlike the icefish, produces Hb at normal 
levels. Starting from a healthy N. coriiceps, we remove Hb and then apply the 
adaptations that allow C. aceratus to thrive: increasing cardiac output by a factor of 
nearly two and allowing for increased cutaneous respiration (44, 45, 48–52). The result 
is a test-fish with several surprising extra-physiologic features, but nevertheless capable 
of survival (Table 4-1). In particular, the ability of C. aceratus to absorb oxygen through 
its skin evokes polydimethylsiloxane (PDMS) – a common polymer in microfluidic and 
biomedical research applications that has similar properties of gas permeability 
(Appendix A). 
In addition to larger-than-expected cardiac output, C. aceratus also has a blood 
volume of ~90 mL/kg, nearly 2x greater than the ~50 mL/kg expected for a fish its size 
(46, 53–56). Another member of Channichthyidae, C. hamatus, has a blood volume 
over two-fold its predicted value (54). These Hb- fish substantially exceed expected 
blood volumes yet thrive (Appendix B), reinforcing the idea that extra-normal physiology 
can be an acceptable mechanism to survive in the face of limitations. Related to that 
increased blood volume, C. aceratus also exhibits increased capillary density. Recent 
results demonstrated that 3 different metrics of vascularization were all ~2x greater in C. 
aceratus than in N. coriiceps (Figure 4-8, A&B) (57). Therefore, even though blood flow 
rates are double in C. aceratus, so too is organ blood volume, indicating that tissue 
residence times – a key parameter in PBPK/PD models – should also remain 
unchanged between it and N. coriiceps.  
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This increased vascularity also helps compensate for dilution of soluble factors 
(e.g. O2, drugs, or hormones) due to increased blood volume. At steady state the 
perfusion-limited diffusion of molecules from blood into tissue is described by Equation 
4-2: 
 𝐷 ⋅ ∇1𝐶 = 𝑅  
Equation 4-2 
where C is the concentration, D is the diffusion coefficient, and R is the uptake of solute 
by cells, governed in this case by Michaelis-Menten kinetics (16, 58). Although a 
decrease in blood concentration leads to a decrease in potential gradient to drive 
diffusion, a corresponding decrease in intervessel distance (IVD) suggests that solute 
penetration may be similar, shown here specifically for O2 (Figure 4-8, C). This icefish 
adaptation is another example of Nature finding a holistic, multi-faceted solution to 
physiologically challenging conditions. Of course, applying designs such as these to an 
HOC may still introduce problems with drugs or molecules that act in a concentration-
dependent mechanism on the blood vessels themselves as well as other unforeseen 
consequences. Conversely, these data also suggest that depletion of soluble factors 
(e.g. oxygen) could be achieved over shorter distances, an important design 
consideration for engineering organ compartments such as the liver (16, 59). 
Nevertheless, this preliminary analysis demonstrates that blood O2 carrying capacity 
and the presence of Hb may be tuned to counter maladaptations – or possibly induce 
more appropriate cellular metabolic behavior. The icefish further suggests that 
increased blood volumes may be accommodated without drastically altering organism 
pharmacokinetics or stromal solute concentration gradients. 
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4.4 A distribution-informed approach to HOC blood volume 
Designing a x10-6 HOC according to QPSRs alone would result in a system blood 
volume of ~6 µL, too small for even cutting-edge microfluidics and an acknowledged 
problem in the field (7, 17, 20, 21, 23). Although a 10x (or greater) increase would yield 
an HOC with a more manageable circulating volume, it would also dilute soluble factors 
and violate QPSRs. Therefore, we adopt a pharmacokinetic approach to investigate 
whether and to what extent the blood volume of an HOC can be increased while 
maintaining physiological relevance.  
When a drug is administered, only a portion circulates dissolved in the blood. 
Accordingly, pharmacologists define volume of distribution, VD (Equation 3-1), to 
describe how much drug is available in the plasma compared to the initial dose (60, 61). 
Conceptually, VD closely resembles a partition coefficient describing the equilibrium 
distribution of a drug between the body and the blood. Using a slightly different 
approach, we consider the distribution of a drug between body water – including blood – 
and tissue. Therefore, this treatment is most applicable to small, perfusion-limited drugs 
without substantial serum protein binding. This ratio, D, is defined by Equation 4-3: 
 𝐷 =	 BCBD  
Equation 4-3 
where D is the distribution coefficient, CT is the concentration of drug in body tissue, and 
CW is the concentration of drug in body water. Introducing terms for the total amount of 
drug in the system (Dose), blood volume (VB), concentration of drug in blood (CB), 
tissue volume (VT), and non-blood water (VO), we rearrange to obtain Equation 4-4: 
  73 
 𝐶* = 	 "EF7GHIGJ I"*GC  
Equation 4-4 
If we apply an arbitrary Z-fold increase to the blood volume compartment and normalize 
the result to the Z=1 condition, CB0, Equation 4-5 follows:  
 𝐶* 𝐶*L = 	 GMIGJ I"*GCGMIN*GJ I"*GC  
Equation 4-5 
In general, CB falls as 1/Z. However, the partitioning properties of the drug and the 
fact that VB is a small fraction of the total system serve to substantially temper the effect 
of increasing Z on blood concentration. For example, this treatment suggests that a 
highly hydrophilic drug, epinephrine, can tolerate ~10x increase in blood volume with 
only a ~2x change in blood concentration. More hydrophobic drugs, such as 
amiodarone, are predicted to show almost no change in blood level at higher values of 
Z, and would require ~106 increase in blood volume to approach that same two-fold 
dilution. 
To test these predictions, we construct a simple model of the body mimicking the 
two-compartment set up of our theoretical treatment. The water compartment – 
including variable blood volume – is represented by phosphate buffered saline and 
tissue is represented by an organic liquid (here, 1-octanol). The concentration of three 
small-molecule drugs – epinephrine, propranolol, and amiodarone – was measured and 
normalized to the Z=1 condition. The data (mean ± S.D.), along with curves resenting 
the values predicted by Equation 4-5 are plotted in Figure 4-9. All three cases show 
reasonable agreement between predicted and experimental values. For scenarios 
where even these small dilutions are unacceptable – or in instances where the 
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preceding treatment does not apply – other pharmacokinetic-based approaches may be 
useful, especially if PDMS or another gas-permeable material is used to decouple O2 
delivery from blood flow rate (Appendix C). 
4.5 HOC design 
4.5.1 Organ compartment design strategy 
As §3.4 demonstrated, it is important to consider both size and function of each 
individual organ compartment of an HOC. Therefore, we use organ structure to 
determine a critical constrained dimension (surface area or volume) and set the organ 
compartment size accordingly. The specific approach, dubbed metabolic functional 
scaling and elucidated Moraes et al. (23),  classifies organs according to principle 
function: 2-dimensional (F-2D) or membranous tissue (e.g. lung) is scaled by surface 
area while functionally 3-dimensional (F-3D) or lobular tissue (e.g. adipose) is scaled by 
volume (23). Rather than relying on the principles of Euclidean geometry – which can 
lead to strange inconsistencies (62) – we scale the critical dimension according the 
expected change in function. Since we propose suppressing cell BMR, eliminating the 
M1/4 change in cellular BMR and therefore inducing a M1 relationship between organism 
size and function, both volume- and surface area-based functions should now scale with 
M1. This is an especially critical insight for F-2D organs since surface area scales as 
V2/3 ~ M2/3 under the principles of simple Euclidean geometry. In this way, MSFS is both 
functionally constrained and metabolically supported. 
This approach, therefore, provides an underlying explanation for the failure of 
purely QPSR- and metabolism-based scaling approaches to capture certain 
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fundamental aspects of biology (62). It also avoids inconsistencies that appear when 
empirical laws are extrapolated outside the range of the original dataset – a key 
problem for applying empirical, allometric organ-organism size relationships to HOC 
design (21, 22). Design parameters for F-2D organs are achieved by scaling according 
to surface area and compartment size is selected to match fluidic shear values found in 
vivo for each tissue. F-3D organs are simply scaled according to mass. For more 
complicated organs such as the liver that may be classified as both F-2D and F-3D, we 
use a two compartment approach: one section with high surface area and another with 
high mass that together approach the appropriate values (Table 4-2). Spheroids and 
other tissue aggregation strategies may be particularly useful in these cases (Appendix 
D). 
The endothelium presents another special case. Since several sources estimate 
the endothelial surface area of the body at 1,000 m2 or greater (63–65), including the 
whole of the endothelium in this HOC would be an impossible undertaking. Since the 
endothelium mainly acts in concert with its associated organ rather than as a distinct 
entity, we include only endothelial tissue from organs already represented in this model 
(lung and liver). These tissues serve to recapitulate EC function within the organs 
included in this design and also provide a readout for general endothelial “health” 
across the HOC. 
In addition to the organs explicitly included in this HOC design, we must also 
account for the body volume not represented by any of the designated organ 
compartments. Including a blank “other organs” zone to represent implied (but absent) 
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organs ensures that our total system mass will be commensurate with that of a macro 
version and other groups have included “missing organ formulators” and “other tissues” 
compartments to similar ends (18, 19, 21, 23). Importantly, since we justify a 
substantially increased blood volume based in part on a volume distribution-based 
treatment that considers the entire body volume, it is critical that that volume be 
faithfully replicated in our model system. 
4.5.2 Overall design parameters 
The insights provided by our examinations of metabolic scaling, C. aceratus’s unique 
physiology, and volume of distribution indicate that we need not be confined by 
preconceived notions of what is or is not “physiologic” in designing an HOC. Instead, it 
is the ultimate response – the function – of the HOC and not the underlying structure 
that is paramount. Specifically: 
1. Without additional controls, on-chip cellular BMR will exceed in vivo levels and 
cause a fundamental mismatch between the model system and reality. We 
propose limiting oxygen delivery as one effective mechanism for controlling 
cellular BMR. 
2. Lack of Hb or an Hb substitute does not doom a vertebrate organism (or an 
HOC) ex ante. In fact, by introducing systemic redundancies and extra-normal 
physiologic values Nature has, and engineers may, successfully addressed such 
anomalies. 
3. Blood volume increases are necessary to address technical limitations of current 
tissue engineering and microfabrication techniques. A distribution-based 
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treatment of supra-physiologic blood volumes and the example of the icefish 
indicate that designers have some latitude in determining HOC blood volume, 
especially for perfusion-limited drugs. 
Finally, we formalize a complete set of design parameters for a lung, liver, 
endothelium, fat, and heart x10-6 HOC (Table 4-3) that follows the design principles laid 
out here. We further compare relevant design criteria of this more practical x10-6 HOC to 
C. aceratus, a standard human, and a mouse (Figure 4-10). Values for this five-
parameter comparison across blood oxygen content (Blood O2), intervessel distance 
(IVD), skin gas exchange, cardiac output, and blood volume were drawn from many 
sources and normalized against values predicted by QPSRs (16, 22, 38, 44, 53, 54, 56, 
57, 66–76). For details, see Appendix E. Another set of charts predicting behavior 
based on theses parameters is calculated and show in (Figure 4-11), demonstrating the 
superiority of our holistic design strategy over an unmodified approach. 
Inspired by the example of C. aceratus and motivated to suppress cellular BMR 
to physiologic levels (and to avoid the challenges inherent in developing a synthetic 
substitute), we have deliberately excluded Hb from this HOC design in order to restrict 
oxygen availability and limit cellular BMR. However, Hb also plays a key role in 
transporting carbon dioxide away from metabolically active tissues – carrying up to 30 
percent of the CO2 transported in blood (38). In this HOC design, we justify ignoring 
these effects because CO2 transport can occur by other means. At 35 °C, PDMS is 
nearly five times more permeable to carbon dioxide than oxygen (77). Similarly, the 
solubility of CO2 and NO (nitrous oxide, an important signaling molecule) in water are 
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both orders of magnitude greater than O2 (78–80). Beyond oxygen transport, Hb plays 
important roles in other aspects of physiology including NO catalysis (38). Depending 
on the specific application, each function may need to be explicitly accounted for in 
HOC design.  
4.5.3 Validation of HOC design strategy 
For this (or any) HOC system to be accepted as a microphysiological model of the 
body, some method of validating the underlying design strategy is necessary. Although 
such a system may not be directly tested against humans we may apply the same 
design criteria outlined here to build rats-, mice-, etc.-on-a-chip. Parallel studies 
comparing the response of the microphysioological model system to the genuine animal 
will provide information on areas where HOCs may be particularly well- (or ill-) suited to 
serve as a complimentary research tool. In and of themselves, these experiments may 
also yield new mechanistic insights into previously unexplored aspects of common 
biomedical research models. 
A second validation approach for this design strategy would be to challenge the 
ability of the HOC system to maintain homeostasis in the face of systemic perturbations. 
Rather than focusing on the response of the system on a specific stimulus, this 
approach focuses on more general aspect of the body that should better port across 
systems, targets, and toxins. For example, any HOC included fat and pancreas 
compartments should be able to regulate the glucose level of the circulating medium. 
Once the system is ready, it should be able to correct an applied glucose bolus (or an 
artificial glucose dearth) by sequestering (mobilizing) glucose as appropriate. Once 
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validate, such a system would be useful for studying any toxins or diseases that affect 
the process. 
4.6 Conclusions 
Quarter power scaling relationships are both empirically and theoretically 
supported and provide guidance for sizing physiologic parameters in the face of 
changing system size. Their application to the development of microphysiological 
models of the body or “humans-on-a-chip,” however, introduces both fundamental and 
technical challenges which currently frustrate efforts at design and construction of a 
relevant, feasible system. We posit that HOC designers may avoid these issues by 
selecting parameters outside the realm of what is considered physiologic so long as the 
ultimate function of the system is preserved. We use a natural experiment, the icefish, 
to conceptually justify this approach and demonstrate how extra-physiologic parameters 
may interact to give a normal physiologic response – essentially using two wrongs to 
make a right. Since cell behavior is context dependent, suppressing cellular BMR on-
chip to mimic in vivo levels is crucial to designing a physiologically relevant HOC. We 
observe a substantial O2-dependent decreases in cell metabolism across four different 
cell types to demonstrate the feasibility of this approach. Further study of an HOC 
system through a distribution-informed treatment of blood concentration of small-
molecule drugs indicates that we may indeed increase HOC blood volumes with only 
minor consequences. In cases where even that is unacceptable, we provide frameworks 
to estimate the magnitude of and/or mitigate the error. Integrating these lessons in the 
design of a liver-lung-heart-fat-blood system, we propose a complete set of design 
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parameters for a x10-6 miniaturized HOC system. This work forms a basis of a Nature-
inspired approach to govern design of in vitro model systems.  
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Figure 4-1. Consequences of context-dependent cell BMR 
(A) Cellular BMR scales as ∝M-¼ in vivo but mammalian cells cultured in vitro have a 
stable BMR (∝M0) regardless of the mass of the source organism. (B) In vitro cell 
culture of human cells leads to a cellular BMR ~1 order of magnitude larger than that of 
a normal human (24, 26). (C) A high fidelity, physiologically relevant HOC will be 
designed with mechanisms to ensure cellular BMR matches typical in vivo values for the 
organism to be modeled. (D) Failure to account for the context-dependent behavior of 
cells can substantially alter the modeled organism-level BMR, especially for larger 
animals (24, 27).  
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Figure 4-2. Metabolically supported scaling 
Metabolically-supported scaling posits that designers must control cellular BMR in order 
to achieve a generalizable, in vivo-like response. A consequence of eliminating the M-¼ 
dependence of cellular BMR is that system BMR scales as M1.  
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Figure 4-3. Seahorse XFe cellular BMR measurement 
To assess the effect of oxygen tension on cellular BMR, we used a Seahorse XFe 
extracellular flux analyzer. (A) The instrument contains a 96-probe array with integrated 
pH and O2 sensors that forms a transient microchamber around the cells. (B) Holding 
that microchamber allows cells to deplete oxygen from their surroundings and we can 
calculate BMR from the rates of change in pH and O2 measurements. Unfortunately, 
cellular metabolic activity alone was insufficient to achieve in vivo like oxygen tension in 
all but one instance. Data plotted as average of n=7 distinct experimental wells per cell 
type.  
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Figure 4-4. Glucose-based cellular BMR measurement 
(A) Cellular uptake data showed a somewhat increasing relationship between glucose 
uptake and oxygen tension for most cell types tested. These data may be refined by 
incorporating a lactate measurement to differentiate between metabolic pathways. 
Moreover, glucose uptake does not necessarily indicate glucose usage for ATP 
production. Data reported as average ± standard deviation, n=12. (B) Per cell ATP 
levels decrease with decreasing oxygen tension for all cell types tested. Data reported 
as average ± standard deviation, n=8; * indicates p<0.05, *** indicates p<0.001 by one 
way ANOVA with Tukey post-hoc test. 
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Figure 4-5. AlamarBlue cellular BMR measurement 
(A) AlamarBlue metabolic indicator was used to measure cellular BMR in different 
oxygen tension environments. Surprisingly, BMR seemed to decrease with increasing 
oxygen – a trend we attribute the mechanism by which AlamarBlue is reduced by 
metabolically active cells (and thus becomes fluorescent). (B) A test to see whether 
oxygen tension affected the re-oxidation of reduced AlamarBlue showed no effect. Data 
plotted as average ± standard deviation for n=7.  
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Figure 4-6. AlamarBlue shows oxygen-induced suppression of cellular BMR 
Using Equation 4-1 to correct for the affect of oxygen tension on AlamarBlue 
metabolism, we show that decreasing oxygen tension consistently surpasses cellular 
BMR across four different human cells lines. Data reported as average ± standard 
deviation, n=8.  
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Figure 4-7. C. aceratus, the icefish 
(A) Artist’s rendering of C. aceratus, a hemoglobin-free fish living in the Southern Ocean 
near Antarctica. Adapted from (43). (B) Freshly drawn blood from C. aceratus (right) is 
milky white while blood from Hb+ N. coriiceps is a familiar shade of red (left). Adapted 
from (46).  
  94 
 
 
Figure 4-8. Oxygen delivery in Nototheniodei 
Retinal micrographs of (A) C. aceratus and (B) N. coriiceps demonstrate the difference 
in capillary density and intervessel distance (IVD) between the two fish. Reprinted from 
(57). (C) These decreased intervessel distances help compensate for low blood O2 
levels in C. aceratus. A similar effect should act on other solute (e.g. growth factors or 
drugs) diluted by larger blood volumes as well. Equation 4-2 solved numerically using 
data from (16, 44, 57, 58).  
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Figure 4-9. Effect of blood volume increase on blood concentration of a drug 
Increased blood volumes minimally effect blood concentration depending on drug 
properties for perfusion-limited drugs according to Equation 4-5. Hydrophobic drugs 
(e.g. amiodarone) partition mostly to tissue and blood concentration is largely 
unaffected by changes in blood volume. More hydrophilic drugs (e.g. epinephrine) 
partition largely to the blood and are more affected by large changes in blood volume.  
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Figure 4-10. HOC design parameter comparison 
Radar charts comparing design parameter values for a human, a mouse, the Hb- icefish 
C. Aceratus, and a x10-6 miniaturized HOC. Values plotted on a log scale and 
normalized to QPSR estimates for all graphs. Note that observed values for the mouse 
and human match QPSR estimates (bold lines) closely while the general shape of the 
charts for C. Aceratus and the HOC have similar shapes. A x10-6 human designed only 
according to QPSR would lie exactly along the bolded line representing a normalized 
value of 1. Computed using data from (16, 22, 38, 44, 53, 54, 56, 57, 66–76).  
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Figure 4-11. Modified HOC design strategy more effective than conventional 
scaling 
Applying the modifications proposed here to build a x10-6 HOC is predicted lead to a 
more accurate model of the human body. Despite straying from conventional 
parameters, our design strategy yields an HOC that more closely matches human levels 
of cellular BMR, total BMR and blood concentration of a low volume distribution drug 
(e.g. epinephrine).  
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Condition 
imposed on N. 
coriiceps 
O2 solubility 
in blood 
[mg / mL]* 
Cardiac 
output (Q) 
[mL / hour] 
Cutaneous 
respiration 
[mg O2 / hour] 
Max O2 delivery 
[mg / hour] 
Fish 
health 
Normal 0.085a 3,900b --- 330 J 
-Hb 0.0095a 3,900 --- 37 L 
-Hb, éQ 0.0095 7,140c --- 68 K 
-Hb, éQ, +C. 
Resp. 0.0095 7,140 10
d 78 J 
 
N. coriiceps resting VO2 = 42 mg O2 / houre 
C. aceratus resting VO2 = 32 mg O2 / hourf 
 
Table 4-1. Hypothetical icefish experiment 
Physiological values for a hypothetical 1 kg test-fish as hemoglobin (Hb) is removed and 
icefish characteristics – increased cardiac output (Q) and cutaneous respiration (C. 
Resp) – are introduced. 
*Measured at 0 ºC and 101.3 kPa 
 
a denotes value from (44), b value from (69), c value from (68), d value adjusted from 
(45), e value from (48, 49), and f value averaged from (48, 49, 53). Values reported in 
literature on a per mass basis are presented here for a test-fish of 1 kg.  
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HOC organ 
compartment 
class 
Tissue size Blood volume 
F-2D Surface area constrained, ∝M
1 
scaling from macro human 
Dimensions selected to maintain 
physiologic shear given fractional cardiac 
output 
F-3D Volume constrained, ∝M
1 
scaling from macro human 
Calculated so that organ blood volume 
matches target fractional organ mass of 
whole body 
F-2.5D Use 3D tissue constructs and/or divide into F-2D and F-3D domains with each domain scaled according to F-2D or F-3D design rules 
 
Table 4-2. HOC organ compartment design strategy 
Design strategy for different HOC organ compartment classes defined by metabolically-
supported function scaling (MSFS) theory.  
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Organ Class 
x10-6 HOC 
SA 
[mm2] 
Tissue 
mass 
[mg] 
Blood 
volume 
[uL] 
% 
BV 
% 
CO 
Compartment dimension 
Length 
[mm] 
Width 
[mm] 
Height 
[mm] 
Lu
ng
 Endothelium F-2D 30 0.12 1.1 --- --- --- --- --- 
Non-EC F-2D 40 0.16 1.4 --- --- --- --- --- 
Total F-2D 70 0.28 2.5 4 100 9.02 7.76 0.035 
Li
ve
r Endothelium F-2D 80 0.32 2 --- --- 14.87 5.38 0.025 
Non-EC F-3D 34 1.75 1.03 --- --- 1.57 1.57 1 
Total F-2/3D 114 2.07 3.03 5 25 --- --- --- 
Heart F-3D --- 0.33 0.28 0.5 4 1.06 1.06 0.5 
Fat F-3D --- 12.5 10.7 18 5 4.96 4.96 1 
Blood --- --- --- 60 --- --- --- --- --- 
“Other tissues” F-3D --- 48.8 43.5 73 66 6.6 6.6 1 
Blood oxygen content [BLO2; mM] ~2 
Cutaneous respiration [mol / m / sec / mmHg] ≤3.8x10-11 
Cardiac output [mL/sec] 3.4x10-3 
Intervessel distance [IVD; μm] 250 
 
Table 4-3. Table of HOC design parameters 
A comprehensive table of design parameters for a five-organ x10-6 HOC. We propose 
increasing blood volume levels beyond those called for by conventional QPSR to 
account for engineering limitations in organ design. Chamber dimensions are selected 
to match in vivo shear levels (F-2D) or match in vivo mass (F-3D). 
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Chapter 5:  
Conclusions and Future Directions 
As bio- and micro- engineering technologies mature, researchers will continue to 
press these advances and develop increasingly complex models of human health (e.g. 
a “human on a chip” or HOC). Certainly, a drastically improved experimental model 
would prove a potent guide to transform life science research and, at its best, usher in a 
new age of exploration in basic science and medicine – a welcome change from the 
current paradigm of reduced efficiency and diminishing returns. Therein lies the rub: 
how can we begin to formulate these generalizable experimental systems? What 
examples can we use? What rules must we follow?  
What rules may we break? 
This dissertation constructed an experimentally- and theoretically-supported 
framework to answer those questions in hopes that a coherent, top-down design 
strategy will form the basis for this next generation of experimental models. To that end, 
Chapter 1 presented the context and motivation for this work.  
In Chapter 2, we develop a well-controlled, cell-dense model of adipose tissue, 
which we characterize with morphological measurements, tissue staining, and 
biomarker analyses. Together, these data indicate that our adipospheroids are not only 
indeed fat, but point to important functional differences between spheroids of different 
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sizes and – importantly – conventional 2D cultures. We confirm those functional 
differences with an insulin-mediated glucose uptake assay. 
In Chapter 3, we leverage the unique properties of our adipospheroid 
microtissues to investigate experimentally what parameters may merit consideration in 
designing an HOC. Our data indicate that metabolism/oxygen, drug/tissue distribution 
behavior, and size/structure must all be carefully accounted for in any approach. 
Chapter 4 applies those lessons as we set out to devise specific design parameters for 
a physiologically relevant, x10-6 HOC. In particular, we find that control of cellular BMR 
and organ compartment design according to function are important principles, an 
approach we dub metabolically supported functional scaling. Additionally, we use a 
distribution-based approach to address technical challenges such as the dilution of 
soluble factors in the circulating media of an HOC. 
These efforts represent concrete steps toward a workable, relevant HOC. 
However, many obstacles remain. The dearth of experimental studies on generalized 
HOCs is an appropriate place to start: focusing on metabolic and homeostatic indicators 
rather than crude dose response relationships (i.e. moving beyond the “drug kills cell” 
model) may not be as appealing in the short run, but will pay dividends over time. 
Developing a self-regulating system or smaller, self-regulating circuits (for example, by 
introducing a pancreas compartment to the experimental setup of §3.4) would serve as 
a far more generalizable platforms and allow researchers to study more nuanced 
phenomena. Life is a delicate, interconnected, and complex – the key advantage of an 
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HOC is to represent that complexity as accurately as possible, but still with some 
degree of control. 
By that same token, designers must continue, like diligent cartographers 
described by Miranda and Wikswo, to search for what details must be included, which 
may be omitted, and how to best represent those whose complexity exceeds our 
modeling capabilities. Technical challenges (such as small circulating media or “blood” 
volumes) are substantial hurdles – especially for the development of a generalized 
experimental platform. Here, clever shortcuts and careful workarounds are essential to 
reduce error to within an order of magnitude or (but preferably and) estimate any 
residual mismatch. These efforts serve an intellectual purpose as well: new technology 
or engineering advances that absolves us of today’s challenges will carry with them 
their own set of difficulties and require the same suite of creative, rational approaches 
examined by this dissertation. Often times, as we saw with the icefish, compromising 
one parameter can rescue another. If well thought out and carefully controlled, two 
wrongs may indeed make a right. 
Throughout this document, the question of how to measure whether a model is 
an accurate mimic of the Natural has lurked just below the surface. In some ways, that 
question sits at this dissertation’s very heart. Whether evaluating a simple, lobular 
microtissue or designing a multi-organ model of the human body, these are fundamental 
issues that may escape scientists who are too often tempted (and too often forced) to 
consider increasingly minute details. Clearly, both the minutia and a broader, rigorous 
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context are important. The great goal, and the great challenge of this effort and others 
like it, is to simultaneously keep focus on both.  
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Appendices 
 
Appendix A: Calculation of C. aceratus skin permeability 
 
The following steps were used to calculate the permeability of C. aceratus’s skin to 
molecular oxygen. The equation 
𝑁 ∗ 𝐴 = 	𝑃 𝐿 (𝐶L − 𝐶S) 
 
Describes transport of gas across a barrier (1) where: 
 N = molar flow O2 [mol O2 / sec] 
  = ~10 mg O2 / hr for a 1 kg C. aceratus (2) 
  = 0.00278 mg O2 / sec 
  = 8.68x10-8 mol O2 / sec 
 A = fish surface area [m2] 
  = 1892 cm2 for a 1 kg C. aceratus (3) 
  = 0.1892 m2 
 L = fish skin thickness [m] 
= ~0.7 mm averaged between sensory line and lateral line values for C. 
aceratus (4) 
  = 7x10-4 m 
 Co = ocean ppO2 [mmHg] 
  = 150 mmHg  
 Ci = C. aceratus blood ppO2 [mmHg] 
  = 120 mmHg from (5) 
P = permeability of C. aceratus skin to oxygen 𝑃 = 	 𝑁𝐿𝐴(𝐶? − 𝐶S) 
 
 = 1.07x10-11 mol O2 * m / m2 / sec / mmHg 
 
Compare to 3.79x10-11 mol O2 * m / m2 / sec / mmHg for PDMS (6) 
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Appendix B: Other details concerning icefish blood volume 
 
Icefish blood volume as a function of body size 
In addition to larger-than-expected cardiac output (mediated by a larger heart 
mass-body mass ratio) (7), C. aceratus also has a blood volume of ~90 mL/kg, nearly 
2x greater than the ~50 mL/kg predicted for a fish its size (2, 8–11). Another member of 
Channichthyidae, C. hamatus, has a blood volume over two-fold its predicted value (8). 
These Hb- fish significantly exceed the blood volume expected from conventional 
QPSRs yet manage to function and flourish. Importantly, this observation reinforces the 
idea that extra-normal parameters can be an acceptable mechanism to thrive in the face 
of surprising physiology. 
Organism Mass [g] Blood volume [mL] Expecteda Observed 
N. coriiceps 900 55 57b 
C. aceratus 1,400 85 126c 
C. hamatus 360 21 46c 
Human 70x103 4.3x103 5.9x103 d 
x10-6 Human 0.07 0.006 --- 
x10-6 HOC 0.07 0.006 0.06 
Expected and actual blood volumes in several Nototheniodae. In addition to the two fish 
considered in the bulk of this study, another species of icefish, C. hamatus, has been 
included to illustrate a second example of elevated blood volumes in Channichthyidae. 
Scaled values for macro and x10-6 miniaturized humans are also included. 
 
a denotes values calculated from Refs. (12, 13) 
b value from Ref (11) 
c value from Ref. (8) 
d value from Ref. (14) 
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Energy cost associate with increased blood volume 
The increased blood volume shown in certain hemoglobin-less (Hb-) 
Channichthyidae species means that C. aceratus’s heart must exert more energy to 
circulate that volume, especially at the high cardiac output required to maintain tissue 
oxygen levels. Researchers have estimated that C. aceratus allocates over one-fifth of 
its energy to driving circulation and that such a cost tradeoff offsets any gains in energy 
conservation made as a result of lower blood viscosity due to the loss of hemoglobin 
(15, 16). While this increased energy demand for circulation (driven mostly by a larger 
stroke volume rather than a faster heart beat) is certainly a concern for C. aceratus (5, 
16, 17), it could easily be addressed in an in vitro system with the use of external assist 
devices, such as pumps (18–20), to make up for the energy deficit imparted by elevated 
blood volumes. 
 
Increased vascular density and vessel bore diameter 
Observations of increased vascular density in C. aceratus (21), made in retinal 
tissue, stand in contrast to other studies of icefish muscle that found decreased capillary 
density (17, 22). These muscle studies, however, also noted larger muscle fiber size in 
Hb- Channichthyidae compared to their Hb+ cousins. One group observed that such an 
increase in size would also decrease the rate of current leak from the muscle, 
conserving a substantial amount of energy and thereby decreasing the metabolic 
demand of the tissue (22). Therefore, measurements made in the retina, where no 
special adaptations (other than increased capillary density, of course) have been 
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observed and oxygen demand is largely activity-level agnostic, may be a more faithful 
representation of the overall character of the fish. Furthermore, the large vessel 
diameters observed in C. aceratus may be explained by constitutive overexpression of 
NO, a potent vasodilator (10, 21). Since Hb-derivatives are involved in the major 
pathway for NO elimination (23), their absence explains this overexpression and 
dictates that capillary diameter may not deviate as sharply from values predicted by 
scaling theory as initial reports indicate (12, 13, 21, 24). In an HOC, NO elimination in 
the absence of Hb may be achieved by incorporating PDMS, which is highly permeable 
to gases (6), as well as taking advantage of the greater solubility of NO in liquid (25).  
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Appendix C: Other pharmacokinetic approaches to compensate for 
high HOC blood volumes for perfusion/transport limited substances 
Classical pharmacokinetic/pharmacodynamics models address inter-organ 
interactions by using rate constants to account for mass transfer between different 
compartments that may effectively capture clinical behavior but have little physiological 
significance. Physiologically-based (PBPK/PD) models explicitly define blood flow as 
the medium by which analytes move between compartments (26). Although PBPK/PD 
models (also referred to as “flow models”) require extensive information about flow 
rates, compartment volumes, and reaction rates, they also require less data fitting, are 
better able to accommodate pathological conditions, and are more easily extrapolated 
to describe PK/PD behavior across species (27). 
In §4.4 of the main text, we explored one way in which specific drug properties 
could be used to improve the efficacy of our HOC with super-physiologic blood volume 
(or estimate the error introduced by such an approach). Here, we further examine 
PBPK/PD approaches to mitigate any residual mismatch between HOC drug 
concentration levels and those that may occur in the body. We sketch out approaches 
to maintain steady state tissue concentration in the face of 1st-order and Michaelis-
Menten reaction kinetics, as well as techniques to hold half-life and area under the 
curve constant from human to HOC. It should be noted that each of these approaches 
comes with its own set of caveats. For example, area under the curve (AUC) can be a 
useful metric for assessing total exposure, but can also mislead when different 
exposure profiles have the same AUC value but fall below or exceed certain critical 
thresholds such as minimum effective concentration or minimum toxic concentration. 
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PBPK/PD treatment to maintain CT-SS with 1st-order kinetics 
PBPK/PD approaches typically idealize individual organ compartments as 
continuous-stirred tank reactors (CSTRs) where mixing times are negligible and the 
concentration of a solute in the compartment is equal to the concentration of the outflow 
(28–30). Assuming 1st-order reaction kinetics where the rate of reaction depends 
linearly on the concentration of the solute of interest within the compartment, as has 
been described previously (30), we begin with the mass (or molar) balance for a 
particular solute in the tissue compartment: 𝑑𝑋V 𝑑𝑡 = 𝑄V ∗ 𝐶? − 𝑄V 𝐾V 𝑋V 𝑉V − 𝑘 ∗ 𝑁B7ZZF 𝑋V 𝑉V 
which describes the mass balance of a CSTR-idealized organ compartment where: 
CO = concentration of solute in the blood 
XT = amount of solute in the organ/itssue compartment 
VT = volume of the tissue compartment 
k = per cell 1th-order reaction rate constant (+ indicates consumption) 
QT = tissue compartment flow rate 
NCells = number of cells in tissue compartment 
KT = partition coefficient between the tissue and blood 
 
Assuming steady state (dXT/dtà0) and replacing XT/VT with CT-SS, the steady-state 
concentration in the tissue compartment, we obtain:  
𝑄V ∗ 𝐶? = 𝐶V[\\ 𝑄V𝐾V + 𝑘 ∗ 𝑁B7ZZF  
Solving for CT-SS yields the following: 
𝐶V[\\ = 𝑄V ∗ 𝐶?𝑄V 𝐾V + 𝑘 ∗ 𝑁B7ZZF 
We now reduce the blood concentration, CO, by a blood volume increase induced 
dilution factor, J (which can be estimated from the distribution-based treatment outlined 
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in §4.4, for example, in the face of a 10x blood volume increase, J=2.28 for epinephrine, 
J=1.06 for propranolol, and J=1 for amiodarone), and introduce a new tissue flow rate, 
PT: 
𝐶V[\\ = 𝑃V 𝐶? 𝐽𝑃V 𝐾V + 𝑘 ∗ 𝑁B7ZZF 
where: J = dilution factor induced by blood volume increase, depends on both drug 
properties (D) and magnitude of blood volume increase (Z) 
Since we wish to maintain CT-SS across both scenarios, we set the two preceding 
equations equal to each other and solve for PT, yielding: 
𝑃V = 	 𝐽 ∗ 𝑄V ∗ 𝑁B7ZZF ∗ 𝑘𝑁B7ZZF ∗ 𝑘 − (𝐽 − 1)𝑄V 𝐾V 
Therefore, if fractional flow rates to each organ and other relevant parameters are 
maintained, a new system flow rate (cardiac output) can be selected to maintain steady-
state tissue level of a specific drug. This approach may be especially useful if another 
method (e.g. incorporation of gas permeable materials such as PDMS) is used to 
decouple oxygen delivery from blood flow. 
 
PBPK/PD treatment to maintain CT-SS with Michaelis-Menten kinetics 
A more complicated, but perhaps more realistic, treatment involves assuming 
Michaelis-Menten reaction kinetics in the organ compartment. We note that MM kinetics 
have previously been used to numerically model oxygen consumption within a 
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bioreactor (31) as well as toxicity of an anti-cancer drug in a 3-organ HOC (29). Starting 
with the mass balance: 
𝑑𝑋V 𝑑𝑡 = 𝑄V𝐶? − 𝑄V 𝐾V 𝑋V 𝑉V − 𝑉_`a 𝑋V 𝑉V𝐾_ + 𝑋V 𝑉V 𝑁B7ZZF 
 
which describes the mass balance of a CSTR-idealized organ compartment where: 
CO = concentration of solute in the blood 
XT = amount of solute in the tissue/organ compartment 
VT = volume of the tissue compartment 
VMax = maximum per cell reaction rate 
KM = the Michaelis constant 
QT = tissue compartment flow rate 
NCells = number of cells in compartment 
KT = partition coefficient between the tissue and blood 
 
Assuming steady state (dXT/dtà0) and replacing XT/VT with CT-SS, the steady-state 
concentration in the tissue compartment, we obtain:  
 𝑄V𝐶? = 𝐶V[\\ 𝑄V 𝐾V + 𝑁B7ZZF 𝑉_`a𝐶V[\\𝐾_ + 𝐶V[\\ 
 
Expanding and collecting terms gives: 
 0 = 𝐶V[\\1 𝑄V 𝐾V + 𝐶V[\\c 𝐾_ 𝑄V 𝐾V − 𝑉_`a − 𝑄V𝐶? + 𝐶V[\\L 𝐾_𝑄V𝐶?  
 
Using the quadratic formula to solve for CT-SS yields: 
 
𝐶V[\\ = 𝑄V𝐶? + 𝑉_`a − 𝐾_ 𝑄V𝐾V ± 𝐾_ 𝑄V𝐾V − 𝑉_`a − 𝑄V𝐶?
1 − 4𝑄V𝐾V 𝐾_𝑄V𝐶?2𝑄V 𝐾V  
 
At this point the analytical treatment becomes quite cumbersome. The interested 
reader may obtain a solution for an adjusted flow rate, PT, as above, or may instead 
choose to solve the problem numerically as done previously (29, 31). 
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PBPK/PD treatment to maintain half-life 
Drug half-life is another important parameter that concerns pharmacologists (32). 
Half-life can be described by the following equation: 
𝐻𝑎𝑙𝑓	𝐿𝑖𝑓𝑒 = 	0.693𝐾o𝑄 𝑉  
where Q = flow rate 
 V = compartment volume 
 KP = equilibrium partition coefficient 
Therefore, half-life is unaffected by changes in blood volume. 
 
PBPK/PD treatment to maintain area under the curve (AUC) 
Area-under-the-curve (AUC) is a common metric for assessing patient dose (33–
35). For example if the clearance of a drug and its metabolites can be assumed to be 
perfusion limited – that is the rate of clearance from the bloodstream is much greater 
than the rate of delivery to clearing organ – decreasing the cardiac output will increase 
the AUC (or vice versa) according to (36):  
𝐴𝑈𝐶 = 	 𝑋𝐹Br ∗ 𝑄 
where X = the amount of drug administered in mg or moles 
FCl = clearance fraction of drug 
Q = cardiac output 
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Thus, even in the face of increased dosing as proposed above, engineering 
modifications can be used to maintain other important pharmacokinetic parameters 
such as AUC. Using an open-source PBPK modeling package, PKQuest, we can 
examine how dose and cardiac output may be manipulated to preserve AUC (37–39). 
Critically, uncoupling these and other parameters – as we have begun to attempt here – 
will offer technologists multiple axes along which to tune exposure profiles and 
represents one potential solution to overcoming the substantial engineering challenges 
of developing a micro-scale model of the human body. 
 
Three arterial concentration curves with different cardiac output-dose parameters but 
identical AUC’s demonstrating how engineering controls can be used to maintain a 
target exposure profile in the face of challenges associated with miniaturization. 
Computed using PKQuest software from Refs (37, 38) and data from Ref (39).  
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Appendix D: Surface area-mass considerations for 3D constructs in 
an HOC system 
3D tissue constructs can lead to improved phenotype and function in vitro for a 
variety of cell types, including liver cells (40). Using 3D aggregates also introduces a 
more complicated relationship between mass and surface area.  For this reason, 
spheroid size and number must be carefully considered during design. Below is a graph 
representing the relationship between HOC organ mass and surface area for spheroids 
of various sizes. Since spheroids of diameter 250 μm have been shown to exhibit 
highest levels of liver specific function (unpublished data), the dashed, purple curve is 
used to inform our design process. 
 
Cell-dense 3-dimensional tissue constructs (spheroids) can control the relationship 
between tissue surface area and volume. Depending on spheroid diameter, different 
surface area-volume curves may be obtained.  
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Appendix E: Derivation of design radar charts 
Table of observed values (with sources) 
 
 
Blood O2 
[mol O2 / m3] 
Blood 
volume [mL] 
Cardiac 
output [mL / 
sec] 
Cutaneous 
respiration 
[mol / m / sec 
/ mmHg] 
Intervessel 
distance 
[μm] 
C. Aceratus 0.3 (41) 125 (8) 2 (16) 1x10-11 (2) 293 (21) 
N. Coriiceps 2.7 (41) 55 (11) 1 (42) 3.5x10-12 (43) 646 (21) 
Human 7 (23) 5900 (14) 112 (14) 3.5x10-12 (43) 200 (44) 
x10-6 HOC ~2 (α) 0.06 (β) 3.4x10-3 (γ) 3.8x10-11 (6) 250 (δ)  
Mouse 5.95 (45) 2 (19) 0.27 (46) 3.5x10-12 (43) 180 (47) 
α – Design consideration to induce in vivo like cellular BMR (see main text §4.2) 
β – Design consideration arrived at by applying QPSR isometric scaling of blood volume to 
miniaturize human by six orders of magnitude. The resulting value (6 μL) is adjusted upwards 
by a factor of 10 to achieve a more workable volume. 
γ – Design consideration arrived at by applying QPSR ¾-power scaling of cardiac output to a 
x10-6 miniaturized human 
δ – Design consideration to accommodate liver spheroids of 250 μm diameter 
 
Table of scaling values (calculated from scaling laws) 
 
 
Mass 
[kg] 
Blood O2 
[mol O2 / 
m3] (ε) 
Blood 
volume 
[mL] (ζ) 
Cardiac 
output [mL 
/ sec] (η) 
Cutaneous 
respiration 
[mol / m / 
sec / 
mmHg] (θ) 
Intervessel 
distance 
[μm] (ι) 
C. Aceratus 1 6.5 60.9 4.44 3.5x10-12 186 
N. Coriiceps 1 6.5 60.9 4.44 3.5x10-12 186 
Human 70 6.5 4263 107.4 3.5x10-12 265 
x10-6 HOC 7x10-5 6.5 6x10-3 3.4x10-3 3.5x10-12 87 
Mouse 0.03 6.5 1.83 0.32 3.5x10-12 139 
ε – Assumed to be mass invariant (∝M0) for Hb+ vertebrates. 
ζ – Calculated according to the equation Y = 60.9*M1. Exponent selected according to scaling 
law and coefficient taken as average of 4 values reported in (13). 
η – Calculated according to the equation Y = 4.44*M0.75. Exponent selected according to scaling 
law and coefficient taken as average of 2 values reported in (13). 
θ – No scaling value known. Permeability of human skin used for all values (43). 
ι – Calculated according to the equation Y = 186*M0.083. Exponent selected according to scaling 
law and, since no literature value could be found, coefficient selected to give reasonable match 
to mouse and human values (12). 
 
Creation of radar charts 
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To create radar graphs of Figure 4-10 of the main text for human, mouse, icefish, 
and x10-6 HOC observed values were normalized against scaling values and plotted 
along five log10 axes in Microsoft Excel. 
 
C. aceratus radar chart normalized against N. coriiceps 
Since C. aceratus is poikilothermic, metabolic values for the fish are likely 
substantially affected by ambient temperature. Although several correction factors have 
been proposed to compare cold-water fish to animals with warmer body temperatures 
(48, 49), no reliable method exists to adjust all relevant parameters considered here. 
One way to circumvent this problem is to normalize C. aceratus to another fish from the 
same environment that can be assumed to follow conventional scaling laws that 
describe most of the rest of the natural world. For completeness, this chart for C. 
aceratus normalized against N. coriiceps is included here. 
Radar chart of C. aceratus normalized to its cousin, N. coriiceps instead of conventional 
parameters predicted by quarter power scaling relationships.  
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